Encompass Health (EHC) 10-Q 29 Oct 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	9 Months Ended
	Sep. 30, 2015	Oct. 22, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	HEALTHSOUTH CORP
Entity Central Index Key	785,161
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		91,437,892
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 3.1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net operating revenues	$ 778.6	$ 596.9	$ 2,283.6	$ 1,792.5
Less: Provision for doubtful accounts	(10.7)	(8.2)	(33.2)	(25)
Net operating revenues less provision for doubtful accounts	767.9	588.7	2,250.4	1,767.5
Operating expenses:
Salaries and benefits	417.1	290	1,204	861.4
Other operating expenses	106.7	89.4	314.1	260.2
Occupancy costs	12.5	10.3	37.1	31.1
Supplies	31	26.6	94.1	82
General and administrative expenses	30.6	27.5	97.3	88.4
Depreciation and amortization	33.7	27.4	98.3	80.2
Government, class action, and related settlements	0	0	8	(0.8)
Professional fees - accounting, tax, and legal	0.4	4	2.7	7.6
Total operating expenses	632	475.2	1,855.6	1,410.1
Loss on early extinguishment of debt	0	0	20	0
Interest expense and amortization of debt discounts and fees	35.6	27.8	98.3	83.5
Other income	(0.7)	(0.2)	(4.2)	(30.1)
Equity in net income of nonconsolidated affiliates	(2.4)	(1.9)	(6.3)	(8.8)
Income from continuing operations before income tax expense	103.4	87.8	287	312.8
Provision for income tax expense	35.9	22.1	98.4	91.4
Income from continuing operations	67.5	65.7	188.6	221.4
Income (loss) from discontinued operations, net of tax	0.3	(0.9)	(1.6)	2.8
Net income	67.8	64.8	187	224.2
Less: Net income attributable to noncontrolling interests	(17.1)	(14.7)	(50.9)	(44.3)
Net income attributable to HealthSouth	50.7	50.1	136.1	179.9
Less: Convertible perpetual preferred stock dividends	0	(1.6)	(1.6)	(4.7)
Net income attributable to HealthSouth common shareholders	$ 50.7	$ 48.5	$ 134.5	$ 175.2
Weighted average common shares outstanding:
Basic	90.6	86.5	89.1	86.8
Diluted	101.5	100.5	101.4	100.7
Basic earnings per share attributable to HealthSouth common shareholders:
Continuing operations	$ 0.56	$ 0.56	$ 1.52	$ 1.96
Discontinued operations	0	(0.01)	(0.02)	0.03
Net Income	0.56	0.55	1.50	1.99
Diluted earnings per share attributable to HealthSouth common shareholders:
Continuing operations	0.52	0.53	1.43	1.82
Discontinued operations	0	(0.01)	(0.02)	0.03
Net income	0.52	0.52	1.41	1.85
Cash dividends per common share	$ 0.23	$ 0.21	$ 0.65	$ 0.57
Amounts attributable to HealthSouth common shareholders:
Income from continuing operations	$ 50.4	$ 51	$ 137.7	$ 177.1
Income (loss) from discontinued operations, net of tax	0.3	(0.9)	(1.6)	2.8
Net income attributable to HealthSouth	$ 50.7	$ 50.1	$ 136.1	$ 179.9

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
COMPREHENSIVE INCOME
Net income	$ 67.8	$ 64.8	$ 187	$ 224.2
Net change in unrealized (loss) gain on available-for-sale securities:
Unrealized net holding (loss) gain arising during the period	(0.7)	(0.2)	0.2	0.5
Reclassifications to net income	(0.6)	0	(1.2)	(0.5)
Other comprehensive loss before income taxes	(1.3)	(0.2)	(1)	0
Provision for income tax benefit related to other comprehensive loss items	0.5	0.1	0.4	0
Other comprehensive loss, net of tax	(0.8)	(0.1)	(0.6)	0
Comprehensive income	67	64.7	186.4	224.2
Comprehensive income attributable to noncontrolling interests	(17.1)	(14.7)	(50.9)	(44.3)
Comprehensive income attributable to HealthSouth	$ 49.9	$ 50	$ 135.5	$ 179.9

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 801.6	$ 66.7	$ 272.3	$ 64.5
Accounts receivable, net of allowance for doubtful accounts of $34.8 in 2015; $22.2 in 2014	350.9	323.2
Deferred income tax assets	185.9	188.4
Other current assets	124.6	108.3
Total current assets	1,463	686.6
Property and equipment, net	1,079.1	1,019.7
Goodwill	1,105	1,084
Intangible assets, net	324.7	306.1
Deferred income tax assets	55.4	129.4
Other long-term assets	222.1	183
Total assets	4,249.3	3,408.8
Current liabilities:
Current portion of long-term debt	23.6	20.8
Accounts payable	65.6	53.4
Accrued expenses and other current liabilities	314.4	290.1
Total current liabilities	403.6	364.3
Long-term debt, net of current portion	2,800.7	2,110.8
Other long-term liabilities	140.7	136.3
Total Liabilities	$ 3,345	$ 2,611.4
Commitments and contingencies
Convertible perpetual preferred stock	$ 0	$ 93.2
Redeemable noncontrolling interests	114.1	84.7
Shareholders' equity:
HealthSouth shareholders’ equity	630.4	473.2
Noncontrolling interests	159.8	146.3
Total shareholders' equity	790.2	619.5	$ 592.8	$ 468.7
Total liabilities and shareholders' equity	$ 4,249.3	$ 3,408.8

Condensed Consolidated Balance5

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Allowance for doubtful accounts	$ 34.8	$ 22.2

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Capital in Excess of Par Value	Accumulated Deficit	Accumulated Other Comprehensive Loss	Treasury Stock	Noncontrolling Interests
Balance at beginning of period at Dec. 31, 2013	$ 468.7	$ 1	$ 2,849.4	$ (2,101.1)	$ (0.1)	$ (404.6)	$ 124.1
Balance at beginning of period, Shares at Dec. 31, 2013		88
Net income	179.9			179.9
Net income attributable to nonredeemable noncontrolling interest	38.9						38.9
Net income, including portion attributable to nonredeemable noncontrolling interest, total	218.8
Receipt of treasury stock	(9.7)					(9.7)
Receipt of treasury stock, Shares		(0.3)
Dividends declared on common stock	(50.6)		(50.6)
Dividends declared on convertible perpetual preferred stock	(4.7)		(4.7)
Stock-based compensation	19.3		19.3
Stock options exercised	7.4		7.4
Stock options exercised, Shares		0.3
Stock warrants exercised	6.3		6.3
Stock warrants exercised, Shares		0.2
Distributions declared	(33.7)						(33.7)
Repurchases of common stock	(43.1)					(43.1)
Repurchases of common stock, Shares		(1.3)
Consolidation of Fairlawn Rehabilitation Hospital	14						14
Other	0.1		0.9			(0.7)	(0.1)
Other, Shares		0.9
Balance at end of period at Sep. 30, 2014	592.8	$ 1	2,828	(1,921.2)	(0.1)	(458.1)	143.2
Balance at end of period, Shares at Sep. 30, 2014		87.8
Balance at beginning of period at Dec. 31, 2014	619.5	$ 1	2,810.5	(1,879.1)	(0.5)	(458.7)	146.3
Balance at beginning of period, Shares at Dec. 31, 2014		87.8
Net income	136.1			136.1
Net income attributable to nonredeemable noncontrolling interest	40.8						40.8
Net income, including portion attributable to nonredeemable noncontrolling interest, total	176.9
Conversion of preferred stock	93.2		93.2
Conversion of preferred stock, shares		3.3
Receipt of treasury stock	(17.2)					(17.2)
Receipt of treasury stock, Shares		(0.6)
Dividends declared on common stock	(59.1)		(59.1)
Dividends declared on convertible perpetual preferred stock	(1.6)		(1.6)
Stock-based compensation	19		19
Stock options exercised	2.2		6.6			(4.4)
Stock options exercised, Shares		0.2
Distributions declared	(36.7)						(36.7)
Capital contributions from consolidated affiliates	9.5						9.5
Fair value adjustments to redeemable noncontrolling interests, net of tax	(14.9)		(14.9)
Other	(0.6)	$ 0.1	1.6		(0.6)	(1.6)	(0.1)
Other, Shares		0.7
Balance at end of period at Sep. 30, 2015	$ 790.2	$ 1.1	$ 2,855.3	$ (1,743)	$ (1.1)	$ (481.9)	$ 159.8
Balance at end of period, Shares at Sep. 30, 2015		91.4

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income	$ 187	$ 224.2
Loss (income) from discontinued operations	1.6	(2.8)
Adjustments to reconcile net income to net cash provided by operating activities-
Provision for doubtful accounts	33.2	25
Government, class action, and related settlements	8	(0.8)
Depreciation and amortization	98.3	80.2
Loss on early extinguishment of debt	20	0
Equity in net income of nonconsolidated affiliates	(6.3)	(8.8)
Distributions from nonconsolidated affiliates	4.5	9.4
Stock-based compensation	21.8	19.3
Deferred tax expense	88	81.6
Gain on consolidation of Fairlawn Rehabilitation Hospital	0	(27.2)
Other	8.2	13
Change in assets and liabilities-
Accounts receivable	(83.7)	(48.7)
Other assets	(8.3)	8.9
Accounts payable	4.4	3.7
Accrued payroll	(16.6)	(8.6)
Accrued interest payable	13.9	4.7
Other liabilities	(3)	(3.7)
Premium received on bond issuance	9.8	6.3
Premium paid on redemption of bonds	(11.8)	0
Net cash used in operating activities of discontinued operations	(0.8)	(1)
Total adjustments	179.6	153.3
Net cash provided by operating activities	368.2	374.7
Cash flows from investing activities:
Purchases of property and equipment	(85.2)	(133.9)
Capitalized software costs	(20.7)	(12.6)
Acquisition of business, net of cash acquired	(87.1)	(15.9)
Proceeds from sale of marketable securities	12.8	2.7
Purchase of Restricted Investments	(6.5)	(2.5)
Other	7.3	(0.1)
Net cash used in investing activities	(179.4)	(162.3)
Cash flows from financing activities:
Principal borrowings under term loan facilities	125	0
Proceeds from bond issuance	1,400	175
Principal payments on debt, including pre-payments	(546.3)	(5.7)
Borrowings on revolving credit facility	315	65
Payments on revolving credit facility	(615)	(110)
Debt amendment and issuance costs	(31.3)	(3.1)
Repurchase of common stock, including fees and expenses	0	(43.1)
Dividends paid on common stock	(56.3)	(47.4)
Dividends paid on convertible perpetual preferred stock	(3.1)	(4.7)
Distributions paid to noncontrolling interests of consolidated affiliates	(39.7)	(39.6)
Other	(2.2)	9
Net cash provided by (used in) financing activities	546.1	(4.6)
Increase in cash and cash equivalents	734.9	207.8
Cash and cash equivalents at beginning of period	66.7	64.5
Cash and cash equivalents at end of period	801.6	272.3
Supplemental schedule of noncash financing activity:
Conversion of preferred stock to common stock	$ 93.2	$ 0

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation HealthSouth Corporation, incorporated in Delaware in 1984, including its subsidiaries, is one of the nation’s largest providers of post-acute healthcare services, offering both facility-based and home-based post-acute services in 33 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. The accompanying unaudited condensed consolidated financial statements of HealthSouth Corporation and Subsidiaries should be read in conjunction with the consolidated financial statements and accompanying notes filed with the United States Securities and Exchange Commission in HealthSouth’s Annual Report on Form 10-K filed on March 2, 2015 (the “ 2014 Form 10-K”). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC applicable to interim financial information. Certain information and note disclosures included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in these interim statements, as allowed by such SEC rules and regulations. The condensed consolidated balance sheet as of December 31, 2014 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, we believe the disclosures are adequate to make the information presented not misleading. The unaudited results of operations for the interim periods shown in these financial statements are not necessarily indicative of operating results for the entire year. In our opinion, the accompanying condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state the financial position, results of operations, and cash flows for each interim period presented. See also Note 11 , Segment Reporting . Net Operating Revenues — We derived consolidated Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Medicare 75.1 % 73.5 % 74.8 % 74.1 % Medicaid 3.4 % 2.2 % 3.0 % 1.8 % Workers’ compensation 0.8 % 1.1 % 0.9 % 1.2 % Managed care and other discount plans, including Medicare Advantage 17.4 % 18.8 % 17.8 % 18.6 % Other third-party payors 1.5 % 1.8 % 1.6 % 1.7 % Patients 0.5 % 1.1 % 0.6 % 1.0 % Other income 1.3 % 1.5 % 1.3 % 1.6 % Total 100.0 % 100.0 % 100.0 % 100.0 % We record gross service charges in our accounting records on an accrual basis using our established rates for the type of service provided to the patient. We recognize an estimated contractual allowance and an estimate of potential subsequent adjustments that may arise from post-payment and other reviews to reduce gross patient charges to the amount we estimate we will actually realize for the service rendered based upon previously agreed to rates with a payor. Our patient accounting system calculates contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital, home health, and hospice provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to HealthSouth under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. The United States Centers for Medicare and Medicaid Services (“CMS”) has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the “HHS-OIG”) or the United States Department of Justice. Therefore, we are unable to predict if or when we may be subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows. Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. We cannot predict when or how these audit programs will affect us. Inpatient Rehabilitation Revenues During the three and nine months ended September 30, 2015 and 2014 , our inpatient rehabilitation segment derived its Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Medicare 73.2 % 73.1 % 73.0 % 73.9 % Medicaid 3.0 % 2.2 % 2.6 % 1.8 % Workers’ compensation 1.0 % 1.1 % 1.1 % 1.2 % Managed care and other discount plans, including Medicare Advantage 18.9 % 19.0 % 19.2 % 18.8 % Other third-party payors 1.7 % 1.9 % 1.9 % 1.7 % Patients 0.6 % 1.1 % 0.7 % 1.0 % Other income 1.6 % 1.6 % 1.5 % 1.6 % Total 100.0 % 100.0 % 100.0 % 100.0 % Revenues recognized by our inpatient rehabilitation segment are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors that are considered and could influence the level of our reserves include the patient’s total length of stay for in-house patients, each patient’s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes, and additional reserves are provided to account for these factors. In connection with CMS approved and announced Recovery Audit Contractors (“RACs”) audits related to inpatient rehabilitation facilities (“IRFs”), we received requests in 2014 and 2013 to review certain patient files for discharges occurring from 2010 to 2014. These post-payment RAC audits are focused on medical necessity requirements for admission to IRFs rather than targeting a specific diagnosis code as in previous pre-payment audits. Medical necessity is an assessment by an independent physician of a patient’s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting. To date, the Medicare payments that are subject to these audit requests represent less than 1% of our Medicare patient discharges from 2010 to 2014, and not all of these patient file requests have resulted in payment denial determinations by the RACs. Because we have confidence in the medical judgment of both the referring and the admitting physicians who assess the treatment needs of their patients, we have appealed substantially all RAC denials arising from these audits using the same process we follow for appealing denials of certain diagnosis codes by Medicare Administrative Contractors (“MACs”) (see “Accounts Receivable and Allowance for Doubtful Accounts” below). Due to the delays announced by CMS in the related adjudication process, we believe the resolution of any claims that are subsequently denied as a result of these RAC audits could take in excess of three years. In addition, because we have limited experience with RACs in the context of post-payment reviews of this nature, we cannot provide assurance as to the future success of these disputes. As such, we make provisions for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for appealing denials of certain diagnosis codes by MACs. As the ultimate results of these audits impact our estimates of amounts determined to be due to HealthSouth under these reimbursement programs, our provision for claims that are part of this post-payment review process are recorded to Net operating revenues . See Note 1, Summary of Significant Accounting Policies , “Net Operating Revenues,” to the consolidated financial statements accompanying the 2014 Form 10-K. Home Health and Hospice Revenues The results of operations for our home health and hospice segment in 2014 included only the results of HealthSouth’s legacy hospital-based home health agencies. During the three and nine months ended September 30, 2015 and 2014 , our home health and hospice segment derived its Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Medicare 84.7 % 97.5 % 84.1 % 96.9 % Medicaid 5.7 % — % 5.7 % — % Workers’ compensation — % 0.4 % — % 0.2 % Managed care and other discount plans, including Medicare Advantage 9.6 % 1.1 % 10.0 % 1.8 % Other third-party payors — % 1.0 % 0.1 % 1.1 % Patients — % — % 0.1 % — % Total 100.0 % 100.0 % 100.0 % 100.0 % Home health and hospice revenues are earned as services are performed either on an episode of care basis, on a per visit basis, or on a daily basis, depending upon the payment terms and conditions established with each payor for services provided. Home Health Under the Medicare home health prospective payment system, we are paid by Medicare based on episodes of care. An episode of care is defined as a length of stay up to 60 days, with multiple continuous episodes allowed. A base episode payment is established by the Medicare program through federal legislation. The base episode payment can be adjusted based on each patient’s health including clinical condition, functional abilities, and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers, and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies. A portion of reimbursement from each Medicare episode is billed near the start of each episode, and cash is typically received before all services are rendered. Revenue for the episode of care is recorded over an average length of treatment period using a calendar day prorating method. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the pro rata number of days in the episode which have been completed as of the period end date. As of September 30, 2015 and December 31, 2014 , the difference between the cash received from Medicare for a request for anticipated payment on episodes in progress and the associated estimated revenue was not material and was recorded in Other current liabilities in our condensed consolidated balance sheets. We are subject to certain Medicare regulations affecting outlier revenue if our patient’s care was unusually costly. Regulations require a cap on all outlier revenue at 10% of total Medicare revenue received by each provider during a cost reporting year. Management has reviewed the potential cap. Reserves recorded for the outlier cap were not material as of September 30, 2015 and December 31, 2014 . For episodic-based rates that are paid by other insurance carriers, including Medicare Advantage, we recognize revenue in a similar manner as discussed above for Medicare revenues. However, these rates can vary based upon the negotiated terms. For non-episodic-based revenue, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual allowances are recorded for the differences between our standard rates and the applicable contracted rates. Hospice Medicare revenues for hospice are recorded on an accrual basis based on the number of days a patient has been on service at amounts equal to an estimated daily or hourly payment rate. The payment rate is dependent on whether a patient is receiving routine home care, general inpatient care, continuous home care or respite care. Adjustments to Medicare revenues are recorded based on an inability to obtain appropriate billing documentation or authorizations acceptable to the payor or other reasons unrelated to credit risk. Hospice companies are subject to two specific payment limit caps under the Medicare program. One limit relates to inpatient care days that exceed 20% of the total days of hospice care provided for the year. The second limit relates to an aggregate Medicare reimbursement cap calculated by the Medicare fiscal intermediary. Currently, we do not believe we are at risk for exceeding these caps and have not recorded a reserve for these caps as of September 30, 2015 or December 31, 2014 . For non-Medicare hospice revenues, we record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients and third parties for services provided and are deducted from gross revenue to determine our net service revenue. We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered. Accounts Receivable and Allowance for Doubtful Accounts— We report accounts receivable at estimated net realizable amounts from services rendered from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers’ compensation programs, employers, and patients. Our accounts receivable are geographically dispersed, but a significant portion of our revenues are concentrated by type of payors. The concentration of net patient service accounts receivable by payor class, as a percentage of total net patient service accounts receivable, is as follows: September 30, 2015 December 31, 2014 Medicare 71.5 % 72.2 % Medicaid 2.8 % 1.8 % Workers' compensation 1.7 % 1.9 % Managed care and other discount plans, including Medicare Advantage 19.0 % 18.5 % Other third-party payors 3.9 % 3.8 % Patients 1.1 % 1.8 % Total 100.0 % 100.0 % While revenues and accounts receivable from the Medicare program are significant to our operations, we do not believe there are significant credit risks associated with this government agency. We do not believe there are any other significant concentrations of revenues from any particular payor that would subject us to any significant credit risks in the collection of our accounts receivable. We provide for accounts receivable that could become uncollectible by establishing an allowance to reduce the carrying value of such receivables to their estimated net realizable value. Additions to the allowance for doubtful accounts are made by means of the Provision for doubtful accounts . We write off uncollectible accounts (after exhausting collection efforts) against the allowance for doubtful accounts. Subsequent recoveries are recorded via the Provision for doubtful accounts . We estimate our allowance for doubtful accounts based on the aging of our accounts receivable, our historical collection experience for each type of payor, and other relevant factors so that the remaining receivables, net of allowances, are reflected at their estimated net realizable values. Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts for patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payor decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When we determine all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency. Accounts are written off after all collection efforts (internal and external) have been exhausted. The collection of outstanding receivables from Medicare, managed care payors, other third-party payors, and patients is our primary source of cash and is critical to our operating performance. While it is our policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where we are (1) unable to obtain verification because the patient’s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, and it takes several days, weeks, or months before qualification for such benefits is confirmed or denied, and (3) the patient is transferred to our hospital from an acute care hospital without having access to a credit card, cash, or check to pay the applicable patient responsibility amounts (i.e., deductibles and co-payments). Our primary collection risks relate to patient responsibility amounts and pre-payment claim reviews conducted by MACs. Patient responsibility amounts include accounts for which the patient was the primary payor or the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient co-payment amounts remain outstanding. Changes in the economy, such as increased unemployment rates or periods of recession, can further exacerbate our ability to collect patient responsibility amounts. For several years, under programs designated as “widespread probes,” certain of our MACs have conducted pre-payment claim reviews of our billings and denied payment for certain diagnosis codes. We dispute, or “appeal,” most of these denials, and we have historically collected approximately 69% of all amounts denied. For claims we choose to take to administrative law judge hearings, we have historically experienced an approximate 73% success rate. The resolution of these disputes can take in excess of three years, and we cannot provide assurance as to our ongoing and future success of these disputes. As such, we make provisions against these receivables in accordance with our accounting policy that necessarily considers historical collection trends of the receivables in this review process as part of our Provision for doubtful accounts . Because we do not write off receivables until all collection efforts have been exhausted, we do not write off receivables related to denied claims while they are in this review process. When the amount collected related to denied claims differs from the net amount previously recorded, these collection differences are recorded in the Provision for doubtful accounts . As a result, the timing of these denials by MACs and their subsequent collection can create volatility in our Provision for doubtful accounts . If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. Changes in general economic conditions, business office operations, payor mix, or trends in federal or state governmental and private employer healthcare coverage could affect our collection of accounts receivable, financial position, results of operations, and cash flows.

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Business Combinations	Business Combinations Inpatient Rehabilitation Reliant Acquisition In October 2015, we completed the previously announced acquisition of the operations of Reliant Hospital Partners, LLC and affiliated entities (“Reliant”). Reliant operates a portfolio of 11 inpatient rehabilitation hospitals in Texas, Massachusetts, and Ohio with a total of 902 beds. Th e total cash consideration delivered at closing was approximately $730 million . With this acquisition, we are able to offer comprehensive, high-quality and cost-effective facility-based and home-based care across new and existing service areas. Supplemental pro forma information and the preliminary purchase price allocation have not been provided as estimates of the fair value of the assets acquired and liabilities assumed have not been completed. See Note 4, Long-term Debt. Other Inpatient Rehabilitation Acquisitions In April 2015, we acquired 83% of the inpatient rehabilitation hospital at Memorial University Medical Center (“Memorial”), a 50 -bed inpatient rehabilitation hospital in Savannah, Georgia, through a joint venture with Memorial Health. The joint venture, which was funded using cash on hand, was not material to our financial position, results of operations, or cash flows. The Memorial transaction was made to enhance our position and ability to provide inpatient rehabilitative services to patients in Savannah and its surrounding areas. As a result of this transaction, Goodwill increased by $0.7 million , none of which is deductible for federal income tax purposes. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital’s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. In May 2015, we acquired Cardinal Hill Rehabilitation Hospital (“Cardinal Hill”), comprised of 158 licensed inpatient rehabilitation beds, 74 licensed skilled nursing beds, and one home health location, in Lexington, Kentucky. This acquisition was made to enhance our position and ability to provide inpatient rehabilitative and home health services to patients in Lexington, Kentucky and its surrounding areas. The acquisition, which was funded using availability under our revolving credit facility, was not material to our financial position, results of operations, or cash flows. Goodwill did not increase as a result of this transaction. We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from their respective dates of acquisition. Assets acquired, liabilities assumed, and noncontrolling interests, if any, were recorded at their estimated fair values as of the respective acquisition dates. The fair values of identifiable intangible assets were based on valuations using the cost and income approaches. The cost approach is based on amounts that would be required to replace the asset (i.e., replacement cost). The income approach, which was also used to estimate the fair value of any noncontrolling interest, is based on management’s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired, if any, was recorded as goodwill. The fair value of the assets acquired and liabilities assumed at the acquisition dates for the inpatient rehabilitation transactions completed in 2015 were as follows (in millions): Total current assets $ 10.1 Property and equipment, net 42.7 Identifiable intangible assets: Noncompete agreements (useful lives of 2 to 3 years) 0.1 Trade names (useful life of 20 years) 0.8 Certificates of need (useful lives of 20 years) 8.8 Licenses (useful life of 20 years) 0.2 Goodwill 0.7 Total assets acquired 63.4 Total liabilities assumed (2.7 ) Net assets acquired $ 60.7 Information regarding the net cash paid for all inpatient rehabilitation acquisitions during each period presented is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Fair value of assets acquired $ — $ — $ 62.8 $ 52.0 Goodwill — — 0.7 34.8 Fair value of liabilities assumed — — (2.7 ) (21.9 ) Fair value of noncontrolling interest owned by joint venture partner — — (4.2 ) (14.0 ) Fair value of equity interest prior to acquisition — — — (35.0 ) Net cash paid for acquisitions $ — $ — $ 56.6 $ 15.9 Home Health and Hospice CareSouth Acquisition In August 2015, Encompass Home Health and Hospice (“Encompass”) entered into a definitive agreement to acquire the home health agency operations of CareSouth Health System, Inc. (“CareSouth”) for a cash purchase price of approximately $170 million . This transaction, which is subject to customary closing conditions and regulatory approvals, is expected to close on November 1, 2015. See Note 4, Long-term Debt. Other Home Health and Hospice Acquisitions During the nine months ended September 30, 2015, we completed the following home health and hospice acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients in the applicable geographic areas. Each acquisition was funded with cash on hand. • In March 2015, we acquired Integrity Home Health Care, Inc. (“Integrity”), a home health company with two locations in the Las Vegas, Nevada area. • In April 2015, we acquired Harvey Home Health Services, Inc. (“Harvey”), a home health company in Houston, Texas. • In May 2015, we acquired Heritage Home Health Care, LLC (“Heritage”), a home health company in Texarkana, Arkansas. • In June 2015, we acquired Washington County Home Health Care, Inc. and Benton County Home Health, Inc., doing business as Alliance Home Health (“Alliance”), a home health company with two locations in the Fayetteville, Arkansas area. • In July 2015, we acquired Southern Utah Home Health, Inc. (“Southern Utah”), a home health and hospice company with two home health locations and two hospice locations in southern Utah. • In July 2015, we acquired Orthopedic Rehab Specialist, LLC (“ORS”), a home health company in Ocala, Florida. We accounted for all of these transactions under the acquisition method of accounting and reported the results of operations of the acquired locations from their respective dates of acquisition. Assets acquired and liabilities assumed were recorded at their estimated fair values as of the respective acquisition dates. The fair values of identifiable intangible assets were based on valuations using the cost and income approaches. The cost approach is based on amounts that would be required to replace the asset (i.e., replacement cost). The income approach is based on management’s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to utilize the acquired locations’ mobile workforce and established relationships within each community and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in these markets. All goodwill recorded as a result of these transactions is deductible for federal income tax purposes. The fair value of the assets acquired at the acquisition date for the home health and hospice transactions completed in 2015 were as follows (in millions): Property and equipment $ 0.1 Identifiable intangible assets: Noncompete agreements (useful lives of 2 to 5 years) 1.3 Trade names (useful lives of 1 year) 0.5 Certificates of need (useful lives of 10 years) 4.9 Licenses (useful lives of 10 years) 3.6 Goodwill 20.3 Total assets acquired 30.7 Total liabilities assumed (0.2 ) Net assets acquired $ 30.5 Information regarding the net cash paid for all home health and hospice acquisitions during each period presented is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Fair value of assets acquired $ 1.9 $ — $ 10.4 $ — Goodwill 7.5 — 20.3 — Fair value of liabilities assumed (0.1 ) — (0.2 ) — Net cash paid for acquisitions $ 9.3 $ — $ 30.5 $ — Pro Forma Results of Operations The following table summarizes the results of operations of the above mentioned transactions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2014 (in millions): Net Operating Revenues Net Income Attributable to HealthSouth Acquired entities only: Actual from acquisition date to September 30, 2015* $ 40.8 $ 0.6 Combined entity: Supplemental pro forma from 07/01/2015-09/30/2015 778.9 50.7 Combined entity: Supplemental pro forma from 07/01/2014-09/30/2014 621.5 51.2 Combined entity: Supplemental pro forma from 01/01/2015-09/30/2015 2,316.3 136.6 Combined entity: Supplemental pro forma from 01/01/2014-09/30/2014 1,863.9 181.3 * Savannah - includes operating results from April 1, 2015 through September 30, 2015 Cardinal Hill - includes operating results from May 1, 2015 through September 30, 2015 Integrity - includes operating results from March 3, 2015 through September 30, 2015 Harvey - includes operating results from April 15, 2015 through September 30, 2015 Heritage - includes operating results from May 1, 2015 through September 30, 2015 Alliance - includes operating results from June 4, 2015 through September 30, 2015 Southern Utah - includes operating results from July 1, 2015 through September 30, 2015 ORS - includes operating results from July 13, 2015 through September 30, 2015 See Note 2, Business Combinations , to the consolidated financial statements accompanying the 2014 Form 10-K for information regarding acquisitions completed in 2014.

Investments in and Advances to

Investments in and Advances to Nonconsolidated Affiliates	9 Months Ended
	Sep. 30, 2015
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Abstract]
Investments in and Advances to Nonconsolidated Affiliates	Investments in and Advances to Nonconsolidated Affiliates As of September 30, 2015 and December 31, 2014 , we had $11.1 million and $9.4 million , respectively, of investments in and advances to nonconsolidated affiliates included in Other long-term assets in our condensed consolidated balance sheets. Investments in and advances to nonconsolidated affiliates represent our investments in nine partially owned subsidiaries, of which eight are general or limited partnerships, limited liability companies, or joint ventures in which HealthSouth or one of its subsidiaries is a general or limited partner, managing member, member, or venturer, as applicable. We do not control these affiliates but have the ability to exercise significant influence over the operating and financial policies of certain of these affiliates. Our ownership percentages in these affiliates range from approximately 1% to 51% . We account for these investments using the cost and equity methods of accounting. The following summarizes the combined results of operations of our equity method affiliates (on a 100% basis, in millions): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Net operating revenues $ 9.2 $ 7.8 $ 26.3 $ 44.1 Operating expenses (4.0 ) (3.3 ) (11.7 ) (22.7 ) Income from continuing operations, net of tax 5.1 4.2 13.8 28.2 Net income 5.1 4.2 13.8 28.2

Long-term Debt

Long-term Debt	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Long-term Debt	Long-term Debt Our long-term debt outstanding consists of the following (in millions): September 30, 2015 December 31, 2014 Credit Agreement— Advances under revolving credit facility $ 25.0 $ 325.0 Term loan facilities 320.0 450.0 Bonds payable— 8.125% Senior Notes due 2020 — 287.0 7.75% Senior Notes due 2022 227.0 227.1 5.125% Senior Notes due 2023 300.0 — 5.75% Senior Notes due 2024 1,215.2 456.2 5.75% Senior Notes due 2025 350.0 — 2.0% Convertible Senior Subordinated Notes due 2043 264.7 258.0 Other notes payable 40.3 41.6 Capital lease obligations 82.1 86.7 2,824.3 2,131.6 Less: Current portion (23.6 ) (20.8 ) Long-term debt, net of current portion $ 2,800.7 $ 2,110.8 The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions): Face Amount Net Amount October 1 through December 31, 2015 $ 3.4 $ 3.4 2016 27.3 27.3 2017 25.6 25.6 2018 25.0 25.0 2019 27.8 27.8 2020 603.0 547.7 Thereafter 2,151.4 2,167.5 Total $ 2,863.5 $ 2,824.3 In December 2014, we drew $375 million under our term loan facilities and $325 million under our revolving credit facility to fund the acquisition of Encompass. See Note 2, Business Combinations , to the consolidated financial statements accompanying the 2014 Form 10‑K. In January 2015, we issued an additional $400 million of our 5.75% Senior Notes due 2024 (the “2024 Notes”) at a price of 102% of the principal amount and used $250 million of the net proceeds to repay borrowings under our term loan facilities, with the remaining net proceeds used to repay borrowings under our revolving credit facility. As a result of the repayment of borrowings under our term loan facility, we recorded a $1.2 million Loss on early extinguishment of debt in the first quarter of 2015. In March 2015, we issued $300 million of 5.125% Senior Notes due 2023 (the “2023 Notes”) at a price of 100.0% of the principal amount, which resulted in approximately $295 million in net proceeds from the public offering. The 2023 Notes are governed by the Base Indenture, as defined in Note 8, Long-term debt , to the consolidated financial statements accompanying the 2014 Form 10-K, and the Fifth Supplemental Indenture dated March 12, 2015. The 2023 Notes mature on March 15, 2023 and bear interest at a per annum rate of 5.125%. Interest on the 2023 Notes is payable semiannually in arrears on March 15 and September 15, beginning on September 15, 2015. We may redeem the 2023 Notes, in whole or in part, at any time on or after March 15, 2018 at the redemption prices set forth below: Period Redemption Price* 2018 103.844 % 2019 102.563 % 2020 101.281 % 2021 and thereafter 100.000 % * Expressed in percentage of principal amount On March 11, 2015, we gave notice of, and made an irrevocable commitment for, the redemption of all the outstanding principal amount of our 8.125% Senior Notes due 2020 (the “2020 Notes”). On April 10, 2015, we used the net proceeds from the 2023 Notes offering, along with cash on hand, to execute the redemption. Pursuant to the terms of the 2020 Notes, this redemption was made at a price of 104.063% , which resulted in a total cash outlay of approximately $302 million to retire the $290 million in principal. As a result of this redemption, we recorded an $18.8 million Loss on early extinguishment of debt in the second quarter of 2015. On June 24, 2015, we amended our existing credit agreement to (1) provide that the leverage ratio financial covenant be calculated on a pro forma basis to include the effects of investments, acquisitions, mergers, and other operational changes and (2) increase the amount of specifically permitted capital lease obligations from $200 million to $350 million . On July 29, 2015, we further amended our credit agreement to (1) add $500 million of new term loan facilities to our existing $600 million revolving credit facility and $195 million of outstanding term loans, (2) change the maximum leverage ratio in the financial covenants applicable for the period July 2015 through June 2017 from 4.25 x to 4.50 x and to 4.25 x from then until maturity, and (3) extend the maturity date for all borrowings to July 2020. Under the terms of the amendment, the amount available to us under the new term loan facilities would be reduced in the event we incurred additional capital markets indebtedness. Based on our issuance of additional senior notes in August 2015 and September 2015, as discussed below, our availability under the new term loan facilities was reduced to $250 million . In September, we borrowed $125 million of the new term loan facilities, the proceeds of which were used to fund a portion of the Reliant acquisition. We intend to utilize the remaining $125 million of term loan facility capacity to finance a portion of the CareSouth acquisition , which is expected to close on November 1, 2015. See Note 2, Business Combinations. In August 2015, we issued an additional $350 million of our 2024 Notes at a price of 100.5% of the principal amount, which resulted in approximately $351 million in net proceeds from the private offering. We used the net proceeds to reduce borrowings under our revolving credit facility and fund a portion of the Reliant acquisition, as discussed in Note 2, Business Combinations. In September 2015, we issued $350 million of 5.75% Senior Notes due 2025 (the “2025 Notes”) at a price of 100.0% of the principal amount, which resulted in approximately $344 million in net proceeds from the private offering. We used the net proceeds from this borrowing to fund a portion of the Reliant acquisition. The 2025 Notes are governed by the Base Indenture, as defined in Note 8, Long-term debt , to the consolidated financial statements accompanying the 2014 Form 10-K, and the Seventh Supplemental Indenture dated September 16, 2015. The 2025 Notes mature on September 15, 2025 and bear interest at a per annum rate of 5.75%. Interest on the 2025 Notes is payable semiannually in arrears on March 15 and September 15, beginning on March 15, 2016. We may redeem the 2025 Notes, in whole or in part, at any time on or after September 15, 2020 at the redemption prices set forth below: Period Redemption Price* 2020 102.875 % 2021 101.917 % 2022 100.958 % 2023 and thereafter 100.000 % * Expressed in percentage of principal amount The net proceeds used in the Reliant acquisition from the private offering of the additional 2024 Notes in August, the private offering of the 2025 Notes in September, and the September draw under our term loan facilities, as discussed above, were invested in short-term interest-bearing instruments and are included in Cash and cash equivalents in our consolidated balance sheet as of September 30, 2015. On October 28, 2015, we gave notice of, and made an irrevocable commitment for, the redemption of $50 million of the outstanding principal amount of our existing 7.75% Senior Notes due 2022. Pursuant to the terms of the 7.75% Senior Notes due 2022, this optional redemption will be at a price of 103.875% , which will result in a total cash outlay of approximately $52 million when the transaction closes, which is expected to be on November 30, 2015. We plan to use cash on hand and borrowings under its senior secured credit facility to fund the redemption. As a result of this redemption, we expect to record an approximate $2 million loss on early extinguishment of debt in the fourth quarter of 2015. For additional information regarding our indebtedness, see Note 8, Long-term Debt, to the consolidated financial statements accompanying the 2014 Form 10-K.

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interests	9 Months Ended
	Sep. 30, 2015
Redeemable Noncontrolling Interests [Abstract]
Redeemable Noncontolling Interests	Redeemable Noncontrolling Interests The following is a summary of the activity related to our Redeemable noncontrolling interests during the nine months ended September 30, 2015 and 2014 (in millions): Nine Months Ended September 30, 2015 2014 Balance at beginning of period $ 84.7 $ 13.5 Net income attributable to noncontrolling interests 10.1 5.4 Distributions declared (5.6 ) (6.7 ) Change in fair value 24.9 — Balance at end of period $ 114.1 $ 12.2 The following table reconciles the net income attributable to nonredeemable Noncontrolling interests , as recorded in the shareholders’ equity section of the condensed consolidated balance sheets, and the net income attributable to Redeemable noncontrolling interests , as recorded in the mezzanine section of the condensed consolidated balance sheets, to the Net income attributable to noncontrolling interests presented in the condensed consolidated statements of operations for the three and nine months ended September 30, 2015 and 2014 (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Net income attributable to nonredeemable noncontrolling interests $ 13.4 $ 12.9 $ 40.8 $ 38.9 Net income attributable to redeemable noncontrolling interests 3.7 1.8 10.1 5.4 Net income attributable to noncontrolling interests $ 17.1 $ 14.7 $ 50.9 $ 44.3

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): Fair Value Measurements at Reporting Date Using As of September 30, 2015 Fair Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Valuation Technique (1) Other current assets: Current portion of restricted marketable securities $ 16.6 $ — $ 16.6 $ — M Other long-term assets: Restricted marketable securities 39.4 — 39.4 — M Redeemable noncontrolling interests 114.1 — — 114.1 I As of December 31, 2014 Other current assets: Current portion of restricted marketable securities $ 4.6 $ — $ 4.6 $ — M Other long-term assets: Option to purchase SCA stock 9.9 — — 9.9 M Restricted marketable securities 45.9 — 45.9 — M Redeemable noncontrolling interests 84.7 — — 84.7 I (1) The three valuation techniques are: market approach (M), cost approach (C), and income approach (I). The fair values of our financial assets and liabilities are determined as follows: • Restricted marketable securities - The fair values of our available-for-sale restricted marketable securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active. • Redeemable noncontrolling interests - The fair value of the Redeemable noncontrolling interest related to our home health segment (see Note 2, Business Combinations , to the consolidated financial statements accompanying the 2014 Form 10‑K) is determined using the product of a twelve-month specified performance measure and a specified median market price multiple based on a basket of public health companies. To determine the fair value of the Redeemable noncontrolling interests in our joint venture hospitals, we use the applicable hospitals’ projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable facilities. The projected operating results use management’s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures. See also Note 5 , Redeemable Noncontrolling Interests . • Option to purchase SCA stock - The fair value of the option to purchase Surgical Care Affiliates (“SCA”) stock was determined using a lattice model. Inputs into the model included the historical price volatility of SCA’s common stock, the risk-free interest rate, and probability factors for the timing of when the option was expected to be exercisable. In connection with the 2007 sale of our surgery centers division, now known as SCA, to ASC Acquisition LLC, an affiliate of TPG Partners V, L.P. (“TPG”), a private investment partnership, we received an option, subject to terms and conditions set forth below, to purchase up to a 5% equity interest in SCA. The price of the option was equal to the original issuance price of the units subscribed for by TPG and certain other co-investors in connection with the acquisition plus a 15% premium, compounded annually. The option had a term of ten years and was exercisable upon certain liquidity events, including a public offering of SCA’s shares of common stock that resulted in 30% or more of SCA’s common stock being listed or traded on a national securities exchange. On November 4, 2013, SCA announced the closing of its initial public offering, which did not reach the 30% threshold to trigger a qualifying liquidity event. During the second quarter of 2014, we entered into an amendment to the option agreement that required us to settle the option net of our exercise price. The addition of this new feature resulted in the option becoming a derivative that must be recorded as an asset or liability on our consolidated balance sheet and marked to market each period. As of December 31, 2014 , the fair value of this option was $9.9 million and is included in Other long-term assets in our condensed consolidated balance sheet. Income from discontinued operations, net of tax for the three and nine months ended September 30, 2014 included a $1.6 million loss and a $5.1 million gain, respectively, resulting from the initial recording of this option as a derivative and its fair value adjustments during the 2014 periods presented. Income from discontinued operations, net of tax for the nine months ended September 30, 2015 included a $0.4 million net loss resulting from the change in fair value of this option from December 31, 2014 to March 31, 2015. On April 1, 2015, TPG closed a secondary offering of SCA common stock, which resulted in greater than 30% of SCA’s common stock being listed or traded on a national securities exchange, and our option became exercisable. On April 9, 2015, we delivered notice of exercise of the option to SCA. On April 13, 2015, SCA settled the net exercise of the option by delivering to us 326,242 shares of SCA common stock. The closing price of the stock on that date was $35.43 per share. Other income for the nine months ended September 30, 2015 included a $2.0 million gain resulting from the change in fair value of this option from April 1, 2015, the date the option became exercisable, to April 13, 2015, the date we settled the net exercise of the option and received shares of SCA common stock. During the second and third quarter of 2015, we sold all of our shares of SCA common stock resulting in realized gains of $0.6 million and $1.2 million that is included in Other income in our condensed statements of operations for the three and nine months ended September 30, 2015 , respectively. In addition to assets and liabilities recorded at fair value on a recurring basis, we are also required to record assets and liabilities at fair value on a nonrecurring basis. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or similar adjustments made to the carrying value of the applicable assets. During the three and nine months ended September 30, 2015 , we did not record any gains or losses related to our nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a nonrecurring basis as part of our continuing operations. As a result of our consolidation of Fairlawn (as defined in Note 2, Business Combinations , to the consolidated financial statements accompanying the 2014 Form 10-K) and the remeasurement of our previously held equity interest at fair value, we recorded a $27.2 million gain as part of Other income during the nine months ended September 30, 2014 . We determined the fair value of our previously held equity interest using the income approach. The income approach included the use of the hospital’s projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the hospital. The projected operating results used management’s best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures. As discussed in Note 1, Summary of Significant Accounting Policies , “Fair Value Measurements,” to the consolidated financial statements accompanying the 2014 Form 10-K, the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our condensed consolidated balance sheets. The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions): As of September 30, 2015 As of December 31, 2014 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Long-term debt: Advances under revolving credit facility $ 25.0 $ 25.0 $ 325.0 $ 325.0 Term loan facilities 320.0 320.0 450.0 450.0 8.125% Senior Notes due 2020 — — 287.0 302.5 7.75% Senior Notes due 2022 227.0 235.9 227.1 240.7 5.125% Senior Notes due 2023 300.0 289.8 — — 5.75% Senior Notes due 2024 1,215.2 1,182.0 456.2 471.4 5.75% Senior Notes due 2025 350.0 340.4 — — 2.00% Convertible Senior Subordinated Notes due 2043 264.7 362.4 258.0 358.4 Other notes payable 40.3 40.3 41.6 41.6 Financial commitments: Letters of credit — 34.2 — 31.8 Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or Level 2 inputs within the fair value hierarchy. See Note 1, Summary of Significant Accounting Policies , “Fair Value Measurements,” to the consolidated financial statements accompanying the 2014 Form 10-K.

Share-Based Payments

Share-Based Payments	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Payments	Share-Based Payments In February and May 2015, we issued a total of 0.5 million restricted stock awards to members of our management team and our board of directors. Approximately 0.2 million of these awards contain only a service condition, while the remainder contain both a service and a performance or market condition. For the awards that include a performance or market condition, the number of shares that will ultimately be granted to employees may vary based on the Company’s performance during the applicable two-year performance measurement period. Additionally, in February 2015, we granted 0.1 million stock options to members of our management team. The fair value of these awards and options was determined using the policies described in Note 1, Summary of Significant Accounting Policies , and Note 13, Share-Based Payments , to the consolidated financial statements accompanying the 2014 Form 10-K.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Our Provision for income tax expense of $35.9 million and $98.4 million for the three and nine months ended September 30, 2015 , respectively, primarily resulted from the application of our estimated effective blended federal and state income tax rate. Our Provision for income tax expense of $22.1 million and $91.4 million for the three and nine months ended September 30, 2014 , respectively, primarily resulted from the application of our estimated effective blended federal and state income tax rates, which were reduced as a result of the nontaxable gain discussed in Note 2, Business Combinations , to the consolidated financial statements accompanying the 2014 Form 10-K related to our acquisition of an additional 30% equity interest in Fairlawn and our election to claim certain tax credits. As a result of the Fairlawn transaction, we released the deferred tax liability associated with the outside basis of our investment in Fairlawn because we now possess sufficient ownership to allow for the historical outside tax basis difference to be resolved through a tax-free transaction in the future. The $241.3 million of net deferred tax assets included in the accompanying condensed consolidated balance sheet as of September 30, 2015 reflects management’s assessment it is more likely than not we will be able to generate sufficient future taxable income to utilize those deferred tax assets based on our current estimates and assumptions. As of September 30, 2015 , we maintained a valuation allowance of $22.9 million due to uncertainties regarding our ability to utilize a portion of our state net operating losses (“NOLs”) before they expire. The amount of the valuation allowance has been determined for each tax jurisdiction based on the weight of all available evidence including management’s estimates of taxable income for each jurisdiction in which we operate over the periods in which the related deferred tax assets will be recoverable. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable state tax jurisdictions, or if the timing of future tax deductions differs from our expectations. We have significant federal and state NOLs that expire in various amounts at varying times through 2031. Our reported federal NOL of $137.4 million (approximately $393 million on a gross basis) as of September 30, 2015 excludes $14.5 million related to operating loss carryforwards resulting from excess tax benefits related to share-based awards, the tax benefits of which, when recognized, will be accounted for as a credit to Capital in excess of par value when they reduce taxes payable. Total remaining gross unrecognized tax benefits were $2.4 million and $0.9 million as of September 30, 2015 and December 31, 2014 , respectively, all of which would affect our effective tax rate if recognized. A reconciliation of the beginning and ending liability for unrecognized tax benefits is as follows (in millions): Gross Unrecognized Income Tax Benefits Balance at December 31, 2014 $ 0.9 Gross amount of increases in unrecognized tax benefits related to prior periods 1.5 Balance at September 30, 2015 $ 2.4 For the tax years that remain open under the applicable statutes of limitation, amounts related to unrecognized tax benefits have been considered by management in its estimate of our potential net recovery of prior years’ income taxes. We do not expect a material change in our unrecognized tax benefits within the next 12 months due to the closing of the applicable statutes of limitation. Our continuing practice is to recognize interest and penalties related to income tax matters in income tax expense. Interest recorded as part of our income tax provision during the three and nine months ended September 30, 2015 and 2014 was not material. Accrued interest income related to income taxes as of September 30, 2015 and December 31, 2014 was not material. In December 2014, we signed an agreement with the IRS to begin participating in their Compliance Assurance Process, a program in which we and the IRS endeavor to agree on the treatment of significant tax positions prior to the filing of our federal income tax return. As a result of this agreement, the IRS surveyed our 2013, 2012, and 2011 federal income tax returns. Our 2014 return has been filed and the IRS has not indicated their intent to examine or survey this return. We have settled federal income tax examinations with the IRS for all tax years through 2010. Our state income tax returns are also periodically examined by various regulatory taxing authorities. We are currently under audit by five states for tax years ranging from 2007 through 2013.

Contingencies and Other Commitm

Contingencies and Other Commitments	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Other Commitments	Contingencies and Other Commitments We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. General Medicine Action— On August 16, 2004, General Medicine, P.C. filed a lawsuit in the Circuit Court of Jefferson County, Alabama (the “Alabama Action”) against us captioned General Medicine, P.C. v. HealthSouth Corp. seeking the recovery of allegedly fraudulent transfers involving assets of Horizon/CMS Healthcare Corporation, a former subsidiary of HealthSouth. General Medicine’s underlying claim against Horizon/CMS originates from a services contract entered into in 1995 between General Medicine and Horizon/CMS whereby General Medicine agreed to provide medical director services to skilled nursing facilities owned by Horizon/CMS for a term of three years . Horizon/CMS terminated the agreement for cause six months after it was executed, and General Medicine then initiated a lawsuit against Horizon/CMS in the United States District Court for the Eastern District of Michigan in 1996 (the “Michigan Action”). General Medicine’s complaint in the Michigan Action alleged that Horizon/CMS breached the services contract by wrongfully terminating General Medicine. We acquired Horizon/CMS in 1997 and sold it to Meadowbrook Healthcare, Inc. in 2001 pursuant to a stock purchase agreement. In 2004, Meadowbrook, without the knowledge of HealthSouth, consented to the entry of a final judgment in the Michigan Action in favor of General Medicine against Horizon/CMS for the alleged wrongful termination of the contract with General Medicine in the amount of $376 million (the “Consent Judgment”). The $376 million damages figure was unilaterally selected by General Medicine and was not tested or opposed by Meadowbrook. Additionally, the settlement agreement (the “Settlement”) used as the basis for the Consent Judgment provided that Meadowbrook would pay only $300,000 to General Medicine to settle the Michigan Action and that General Medicine would seek to recover the remaining balance of the Consent Judgment solely from us. We were not a party to the Michigan Action, the Settlement negotiated by Meadowbrook, or the Consent Judgment. The complaint filed by General Medicine against us in the Alabama Action alleged that while Horizon/CMS was our wholly owned subsidiary, General Medicine was an existing creditor of Horizon/CMS by virtue of the breach of contract claim underlying the Settlement. The complaint also alleged we caused Horizon/CMS to transfer its assets to us for less than a reasonably equivalent value or, in the alternative, with the actual intent to defraud creditors of Horizon/CMS, including General Medicine, in violation of the Alabama Uniform Fraudulent Transfer Act. General Medicine further alleged in its amended complaint that we were liable for the Consent Judgment despite not being a party to it because as Horizon/CMS’s parent we failed to observe corporate formalities in our operation and ownership of Horizon/CMS, misused our control of Horizon/CMS, stripped assets from Horizon/CMS, and engaged in other conduct which amounted to a fraud on Horizon/CMS’s creditors. General Medicine requested relief including recovery of the unpaid amount of the Consent Judgment, the avoidance of the subject transfers of assets, attachment of the assets transferred to us, appointment of a receiver over the transferred properties, and a monetary judgment for the value of properties transferred. We denied liability to General Medicine and asserted defenses and a counterclaim against General Medicine that the Consent Judgment was the product of collusion by General Medicine and Meadowbrook. Consequently, we asserted that the Consent Judgment was not evidence of a legitimate debt owed by Horizon/CMS to General Medicine that was collectible from HealthSouth under any theory of liability. The trial in the Alabama Action began on March 9, 2015. On March 22, 2015, we entered into an agreement with General Medicine to settle the Alabama Action . Although the specific terms of this settlement agreement are confidential, both parties agreed to dismiss with prejudice the lawsuit pending in the Circuit Court of Jefferson County, Alabama and to release all claims between the parties. In exchange for General Medicine’s release, we agreed to pay an amount of cash that is not material. Other Litigation— We have been named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned Nichols v. HealthSouth Corp . The plaintiffs allege that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiffs are seeking compensatory and punitive damages. This case was consolidated with the Tucker case for discovery and other pretrial purposes and was stayed in the Circuit Court on August 8, 2005. The plaintiffs filed an amended complaint on November 9, 2010 to which we responded with a motion to dismiss filed on December 22, 2010. During a hearing on February 24, 2012, plaintiffs’ counsel indicated his intent to dismiss certain claims against us. Instead, on March 9, 2012, the plaintiffs amended their complaint to include additional securities fraud claims against HealthSouth and add several former officers to the lawsuit. On September 12, 2012, the plaintiffs further amended their complaint to request certification as a class action. One of those named officers has repeatedly attempted to remove the case to federal district court, most recently on December 11, 2012. We filed our latest motion to remand the case back to state court on January 10, 2013. On September 27, 2013, the federal court remanded the case back to state court. On November 25, 2014, the plaintiffs filed another amended complaint to assert new allegations relating to the time period of 1997 to 2002. On December 10, 2014, we filed a motion to dismiss on the grounds the plaintiffs lack standing because their claims are derivative in nature, and the claims are time-barred by the statute of limitations. A hearing on our motion has not yet been set. We intend to vigorously defend ourselves in this case. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case. Governmental Inquiries and Investigations— On June 24, 2011, we received a document subpoena addressed to HealthSouth Hospital of Houston, a long-term acute care hospital (“LTCH”) we closed in August 2011, and issued from the Dallas, Texas office of the HHS-OIG. The subpoena stated it was in connection with an investigation of possible false or otherwise improper claims submitted to Medicare and Medicaid and requested documents and materials relating to patient admissions, length of stay, and discharge matters at this closed LTCH. We furnished the documents requested and have heard nothing from the HHS-OIG since December 2012. On March 4, 2013, we received document subpoenas from an office of the HHS-OIG addressed to four of our hospitals. Those subpoenas also requested complete copies of medical records for 100 patients treated at each of those hospitals between September 2008 and June 2012. The investigation is being conducted by the United States Department of Justice (the “DOJ”). On April 24, 2014, we received document subpoenas relating to an additional seven of our hospitals. The new subpoenas reference substantially similar investigation subject matter as the original subpoenas and request materials from the period January 2008 through December 2013. Two of the four hospitals addressed in the original set of subpoenas have received supplemental subpoenas to cover this new time period. The most recent subpoenas do not include requests for specific patient files. However, in February 2015, the DOJ requested the voluntary production of the medical records of an additional 70 patients, some of whom were treated in hospitals not subject to the subpoenas, and we provided these records. All of the subpoenas are in connection with an investigation of alleged improper or fraudulent claims submitted to Medicare and Medicaid and request documents and materials relating to practices, procedures, protocols and policies, of certain pre- and post-admissions activities at these hospitals including, among other things, marketing functions, pre-admission screening, post-admission physician evaluations, patient assessment instruments, individualized patient plans of care, and compliance with the Medicare 60% rule. Under the Medicare rule commonly referred to as the “ 60% rule,” an inpatient rehabilitation hospital must treat 60% or more of its patients from at least one of a specified list of medical conditions in order to be reimbursed at the inpatient rehabilitation hospital payment rates, rather than at the lower acute care hospital payment rates. We are cooperating fully with the DOJ in connection with these subpoenas and are currently unable to predict the timing or outcome of the related investigations. Other Matters— The False Claims Act, 18 U.S.C. § 287, allows private citizens, called “relators,” to institute civil proceedings alleging violations of the False Claims Act. These qui tam cases are generally sealed by the court at the time of filing. The only parties typically privy to the information contained in the complaint are the relator, the federal government, and the presiding court. It is possible that qui tam lawsuits have been filed against us and that those suits remain under seal or that we are unaware of such filings or prevented by existing law, court order, or agreement with the government from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed qui tam cases brought pursuant to the False Claims Act. It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and the United States Centers for Medicare and Medicaid Services relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, HealthSouth refunding amounts to Medicare or other federal healthcare programs.

Segment Reporting Segment Repor

Segment Reporting Segment Reporting	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Segment Reporting As described in Note 2, Business Combinations , to the consolidated financial statements accompanying the 2014 Form10-K, on December 31, 2014, we completed the acquisition of Encompass. As a result of this transaction, in the first quarter of 2015, management changed the way it manages and operates the consolidated reporting entity and modified the reports used by our chief operating decision maker to assess performance and allocate resources. These changes required us to revise our segment reporting from our historic presentation of only one reportable segment. Our internal financial reporting and management structure is focused on the major types of services provided by HealthSouth. Beginning in the first quarter of 2015, we manage our operations using two operating segments which are also our reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. Prior period information has been adjusted to conform to the current period presentation. Specifically, HealthSouth’s legacy 25 hospital-based home health agencies have been reclassified from our inpatient rehabilitation segment to our home health and hospice segment for all periods presented. These reportable operating segments are consistent with information used by our chief executive officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments: • Inpatient Rehabilitation - Our national network of inpatient rehabilitation hospitals stretches across 29 states and Puerto Rico, with a concentration of hospitals in the eastern half of the United States and Texas. As of September 30, 2015 , we operate 109 inpatient rehabilitation hospitals, including one hospital that operates as a joint venture which we account for using the equity method of accounting. In addition, we manage three inpatient rehabilitation units through management contracts. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. Our inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. • Home Health and Hospice - As of September 30, 2015 , we provide home health and hospice services in 164 locations across 18 states. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. We also provide specialized home care services in Texas and Kansas for pediatric patients with severe medical conditions. Our hospice services primarily include in-home services to terminally ill patients and their families to address patients’ physical needs, including pain control and symptom management, and to provide emotional and spiritual support. The accounting policies of our reportable segments are the same as those described in Note 1, Basis of Presentation , “Net Operating Revenues” and “Accounts Receivable and Allowance for Doubtful Accounts” to these condensed consolidated financial statements and Note 1, Summary of Significant Accounting Policies , to the consolidated financial statements accompanying the 2014 Form 10-K. All revenues for our services are generated through external customers. See Note 1, Basis of Presentation , “Net Operating Revenues,” for the payor composition of our revenues. No corporate overhead is allocated to either of our reportable segments. Our chief operating decision maker evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (“Segment Adjusted EBITDA”). Selected financial information for our reportable segments is as follows (in millions): Inpatient Rehabilitation Home Health and Hospice Three Months Ended September 30, Nine Months Ended September 30, Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 2015 2014 2015 2014 Net operating revenues $ 651.6 $ 589.9 $ 1,927.2 $ 1,771.5 $ 127.0 $ 7.0 $ 356.4 $ 21.0 Less: Provision for doubtful accounts (10.2 ) (8.1 ) (31.4 ) (24.7 ) (0.5 ) (0.1 ) (1.8 ) (0.3 ) Net operating revenues less provision for doubtful accounts 641.4 581.8 1,895.8 1,746.8 126.5 6.9 354.6 20.7 Operating expenses: Inpatient rehabilitation: Salaries and benefits 326.8 285.0 950.8 846.1 — — — — Other operating expenses 95.8 86.1 284.5 252.8 — — — — Supplies 28.9 26.5 88.6 81.7 — — — — Occupancy costs 10.6 10.2 31.7 30.8 — — — — Home health and hospice: Cost of services sold (excluding depreciation and amortization) — — — — 61.7 4.1 171.8 12.5 Support and overhead costs — — — — 42.6 1.7 121.7 5.1 462.1 407.8 1,355.6 1,211.4 104.3 5.8 293.5 17.6 Other income (0.1 ) (0.2 ) (1.0 ) (2.9 ) — — — — Equity in net income of nonconsolidated affiliates (2.4 ) (1.9 ) (6.3 ) (8.8 ) — — — — Noncontrolling interests 15.6 14.6 46.4 44.0 1.5 0.1 4.5 0.3 Segment Adjusted EBITDA $ 166.2 $ 161.5 $ 501.1 $ 503.1 $ 20.7 $ 1.0 $ 56.6 $ 2.8 Capital expenditures $ 43.8 $ 46.1 $ 103.2 $ 146.6 $ 0.5 $ — $ 2.7 $ — Inpatient Rehabilitation Home Health and Hospice HealthSouth Consolidated As of September 30, 2015 Total assets $ 3,419.4 $ 894.2 $ 4,249.3 Investments in and advances to nonconsolidated affiliates 11.1 — 11.1 As of December 31, 2014 Total assets $ 2,596.8 $ 876.3 $ 3,408.8 Investments in and advances to nonconsolidated affiliates 9.4 — 9.4 Segment reconciliations (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Total segment Adjusted EBITDA $ 186.9 $ 162.5 $ 557.7 $ 505.9 General and administrative expenses (30.6 ) (27.5 ) (97.3 ) (88.4 ) Depreciation and amortization (33.7 ) (27.4 ) (98.3 ) (80.2 ) Loss on disposal or impairment of assets (0.9 ) (2.7 ) (0.2 ) (5.7 ) Government, class action, and related settlements — — (8.0 ) 0.8 Professional fees - accounting, tax, and legal (0.4 ) (4.0 ) (2.7 ) (7.6 ) Loss on early extinguishment of debt — — (20.0 ) — Interest expense and amortization of debt discounts and fees (35.6 ) (27.8 ) (98.3 ) (83.5 ) Gain on consolidation of former equity method hospital — — — 27.2 Net income attributable to noncontrolling interests 17.1 14.7 50.9 44.3 Gain related to SCA equity interest 0.6 — 3.2 — Income from continuing operations before income tax expense $ 103.4 $ 87.8 $ 287.0 $ 312.8 September 30, 2015 December 31, 2014 Total assets for reportable segments $ 4,313.6 $ 3,473.1 Reclassification of noncurrent deferred income tax liabilities to net noncurrent deferred income tax assets (64.3 ) (64.3 ) Total consolidated assets $ 4,249.3 $ 3,408.8 Additional detail regarding the revenues of our operating segments by service line follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Inpatient rehabilitation: Inpatient $ 625.1 $ 563.7 $ 1,850.4 $ 1,691.6 Outpatient and other 26.5 26.2 76.8 79.9 Total inpatient rehabilitation 651.6 589.9 1,927.2 1,771.5 Home health and hospice: Home health 118.3 7.0 333.7 21.0 Hospice 8.7 — 22.7 — Total home health and hospice 127.0 7.0 356.4 21.0 Total net operating revenues $ 778.6 $ 596.9 $ 2,283.6 $ 1,792.5

Condensed Consolidating Financi

Condensed Consolidating Financial Information	9 Months Ended
	Sep. 30, 2015
Condensed Consolidating Financial Information [Abstract]
Condensed Consolidating Financial Information	The accompanying condensed consolidating financial information has been prepared and presented pursuant to SEC Regulation S-X, Rule 3-10, “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” Each of the subsidiary guarantors is 100% owned by HealthSouth, and all guarantees are full and unconditional and joint and several, subject to certain customary conditions for release. HealthSouth’s investments in its consolidated subsidiaries, as well as guarantor subsidiaries’ investments in nonguarantor subsidiaries and nonguarantor subsidiaries’ investments in guarantor subsidiaries, are presented under the equity method of accounting with the related investment presented within the line items Intercompany receivable and investments in consolidated affiliates and Intercompany payable in the accompanying condensed consolidating balance sheets. The terms of our credit agreement allow us to declare and pay cash dividends on our common stock so long as: (1) we are not in default under our credit agreement and (2) our senior secured leverage ratio (as defined in our credit agreement) remains less than or equal to 1.75 x. The terms of our senior note indenture allow us to declare and pay cash dividends on our common stock so long as (1) we are not in default, (2) the consolidated coverage ratio (as defined in the indenture) exceeds 2 x or we are otherwise allowed under the indenture to incur debt, and (3) we have capacity under the indenture’s restricted payments covenant to declare and pay dividends. See Note 8, Long-term Debt , to the consolidated financial statements accompanying the 2014 Form 10-K. In the first quarter of 2015, we revised our condensed consolidating balance sheet as of December 31, 2014 to correct the classification of $51.4 million of net noncurrent deferred tax liabilities of our Nonguarantor Subsidiaries from noncurrent Deferred income tax assets to Other long-term liabilities . The impact of this revision was to increase total assets and increase liabilities for Nonguarantor Subsidiaries, with an offset to Eliminating Entries. This revision is not material to the related financial statements as of and for the year ended December 31, 2014 and had no impact on our condensed consolidated balance sheet as of December 31, 2014. Periodically, certain wholly owned subsidiaries of HealthSouth make dividends or distributions of available cash and/or intercompany receivable balances to their parents. In addition, HealthSouth makes contributions to certain wholly owned subsidiaries. When made, these dividends, distributions, and contributions impact the Intercompany receivable , Intercompany payable , and HealthSouth shareholders’ equity line items in the accompanying condensed consolidating balance sheet but have no impact on the consolidated financial statements of HealthSouth Corporation. Three Months Ended September 30, 2015 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 4.3 $ 468.6 $ 331.7 $ (26.0 ) $ 778.6 Less: Provision for doubtful accounts — (7.7 ) (3.0 ) — (10.7 ) Net operating revenues less provision for doubtful accounts 4.3 460.9 328.7 (26.0 ) 767.9 Operating expenses: Salaries and benefits 14.7 218.9 187.7 (4.2 ) 417.1 Other operating expenses 6.5 68.2 42.0 (10.0 ) 106.7 Occupancy costs 1.1 16.9 6.3 (11.8 ) 12.5 Supplies — 20.2 10.8 — 31.0 General and administrative expenses 27.8 — 2.8 — 30.6 Depreciation and amortization 2.6 20.0 11.1 — 33.7 Professional fees—accounting, tax, and legal 0.4 — — — 0.4 Total operating expenses 53.1 344.2 260.7 (26.0 ) 632.0 Interest expense and amortization of debt discounts and fees 33.4 2.1 2.7 (2.6 ) 35.6 Other income (2.5 ) (0.1 ) (0.7 ) 2.6 (0.7 ) Equity in net income of nonconsolidated affiliates — (2.4 ) — — (2.4 ) Equity in net income of consolidated affiliates (80.4 ) (9.2 ) — 89.6 — Management fees (29.2 ) 22.2 7.0 — — Income from continuing operations before income tax (benefit) expense 29.9 104.1 59.0 (89.6 ) 103.4 Provision for income tax (benefit) expense (20.5 ) 39.5 16.9 — 35.9 Income from continuing operations 50.4 64.6 42.1 (89.6 ) 67.5 Income from discontinued operations, net of tax 0.3 — — — 0.3 Net income 50.7 64.6 42.1 (89.6 ) 67.8 Less: Net income attributable to noncontrolling interests — — (17.1 ) — (17.1 ) Net income attributable to HealthSouth $ 50.7 $ 64.6 $ 25.0 $ (89.6 ) $ 50.7 Comprehensive income $ 49.9 $ 64.6 $ 42.1 $ (89.6 ) $ 67.0 Comprehensive income attributable to HealthSouth $ 49.9 $ 64.6 $ 25.0 $ (89.6 ) $ 49.9 Three Months Ended September 30, 2014 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 4.0 $ 424.5 $ 191.2 $ (22.8 ) $ 596.9 Less: Provision for doubtful accounts — (5.7 ) (2.5 ) — (8.2 ) Net operating revenues less provision for doubtful accounts 4.0 418.8 188.7 (22.8 ) 588.7 Operating expenses: Salaries and benefits 4.1 197.9 91.8 (3.8 ) 290.0 Other operating expenses 5.0 62.0 31.8 (9.4 ) 89.4 Occupancy costs 1.1 14.5 4.3 (9.6 ) 10.3 Supplies 0.1 18.6 7.9 — 26.6 General and administrative expenses 27.5 — — — 27.5 Depreciation and amortization 2.3 18.2 6.9 — 27.4 Professional fees—accounting, tax, and legal 4.0 — — — 4.0 Total operating expenses 44.1 311.2 142.7 (22.8 ) 475.2 Interest expense and amortization of debt discounts and fees 25.7 1.7 0.7 (0.3 ) 27.8 Other income 0.1 — (0.6 ) 0.3 (0.2 ) Equity in net income of nonconsolidated affiliates — (1.9 ) — — (1.9 ) Equity in net income of consolidated affiliates (62.6 ) (7.2 ) — 69.8 — Management fees (26.8 ) 20.4 6.4 — — Income from continuing operations before income tax (benefit) expense 23.5 94.6 39.5 (69.8 ) 87.8 Provision for income tax (benefit) expense (27.5 ) 39.2 10.4 — 22.1 Income from continuing operations 51.0 55.4 29.1 (69.8 ) 65.7 Loss from discontinued operations, net of tax (0.9 ) — — — (0.9 ) Net income 50.1 55.4 29.1 (69.8 ) 64.8 Less: Net income attributable to noncontrolling interests — — (14.7 ) — (14.7 ) Net income attributable to HealthSouth $ 50.1 $ 55.4 $ 14.4 $ (69.8 ) $ 50.1 Comprehensive income $ 50.0 $ 55.4 $ 29.1 $ (69.8 ) $ 64.7 Comprehensive income attributable to HealthSouth $ 50.0 $ 55.4 $ 14.4 $ (69.8 ) $ 50.0 Nine Months Ended September 30, 2015 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 14.7 $ 1,394.8 $ 950.5 $ (76.4 ) $ 2,283.6 Less: Provision for doubtful accounts — (25.0 ) (8.2 ) — (33.2 ) Net operating revenues less provision for doubtful accounts 14.7 1,369.8 942.3 (76.4 ) 2,250.4 Operating expenses: Salaries and benefits 35.0 647.0 534.5 (12.5 ) 1,204.0 Other operating expenses 22.7 199.6 122.4 (30.6 ) 314.1 Occupancy costs 3.2 48.6 18.6 (33.3 ) 37.1 Supplies — 62.2 31.9 — 94.1 General and administrative expenses 93.6 — 3.7 — 97.3 Depreciation and amortization 7.3 58.7 32.3 — 98.3 Government, class action, and related settlements 8.0 — — — 8.0 Professional fees—accounting, tax, and legal 2.7 — — — 2.7 Total operating expenses 172.5 1,016.1 743.4 (76.4 ) 1,855.6 Loss on early extinguishment of debt 20.0 — — — 20.0 Interest expense and amortization of debt discounts and fees 91.0 6.6 8.2 (7.5 ) 98.3 Other income (9.6 ) (0.2 ) (1.9 ) 7.5 (4.2 ) Equity in net income of nonconsolidated affiliates — (6.3 ) — — (6.3 ) Equity in net income of consolidated affiliates (241.0 ) (25.4 ) — 266.4 — Management fees (87.0 ) 66.2 20.8 — — Income from continuing operations before income tax (benefit) expense 68.8 312.8 171.8 (266.4 ) 287.0 Provision for income tax (benefit) expense (68.9 ) 118.9 48.4 — 98.4 Income from continuing operations 137.7 193.9 123.4 (266.4 ) 188.6 Loss from discontinued operations, net of tax (1.6 ) — — — (1.6 ) Net income 136.1 193.9 123.4 (266.4 ) 187.0 Less: Net income attributable to noncontrolling interests — — (50.9 ) — (50.9 ) Net income attributable to HealthSouth $ 136.1 $ 193.9 $ 72.5 $ (266.4 ) $ 136.1 Comprehensive income $ 135.5 $ 193.9 $ 123.4 $ (266.4 ) $ 186.4 Comprehensive income attributable to HealthSouth $ 135.5 $ 193.9 $ 72.5 $ (266.4 ) $ 135.5 Nine Months Ended September 30, 2014 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 11.5 $ 1,286.4 $ 561.7 $ (67.1 ) $ 1,792.5 Less: Provision for doubtful accounts — (17.6 ) (7.4 ) — (25.0 ) Net operating revenues less provision for doubtful accounts 11.5 1,268.8 554.3 (67.1 ) 1,767.5 Operating expenses: Salaries and benefits 15.9 590.2 266.6 (11.3 ) 861.4 Other operating expenses 15.0 182.1 90.0 (26.9 ) 260.2 Occupancy costs 3.1 43.4 13.5 (28.9 ) 31.1 Supplies — 57.9 24.1 — 82.0 General and administrative expenses 88.4 — — — 88.4 Depreciation and amortization 7.4 54.1 18.7 — 80.2 Government, class action, and related settlements (0.8 ) — — — (0.8 ) Professional fees—accounting, tax, and legal 7.6 — — — 7.6 Total operating expenses 136.6 927.7 412.9 (67.1 ) 1,410.1 Interest expense and amortization of debt discounts and fees 76.3 5.9 2.1 (0.8 ) 83.5 Other income (0.3 ) (28.4 ) (2.2 ) 0.8 (30.1 ) Equity in net income of nonconsolidated affiliates — (8.8 ) — — (8.8 ) Equity in net income of consolidated affiliates (233.9 ) (21.3 ) — 255.2 — Management fees (80.7 ) 61.6 19.1 — — Income from continuing operations before income tax (benefit) expense 113.5 332.1 122.4 (255.2 ) 312.8 Provision for income tax (benefit) expense (63.5 ) 122.0 32.9 — 91.4 Income from continuing operations 177.0 210.1 89.5 (255.2 ) 221.4 Income (loss) from discontinued operations, net of tax 2.9 — (0.1 ) — 2.8 Net income 179.9 210.1 89.4 (255.2 ) 224.2 Less: Net income attributable to noncontrolling interests — — (44.3 ) — (44.3 ) Net income attributable to HealthSouth $ 179.9 $ 210.1 $ 45.1 $ (255.2 ) $ 179.9 Comprehensive income $ 179.9 $ 210.1 $ 89.4 $ (255.2 ) $ 224.2 Comprehensive income attributable to HealthSouth $ 179.9 $ 210.1 $ 45.1 $ (255.2 ) $ 179.9 As of September 30, 2015 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 786.7 $ 0.1 $ 14.8 $ — $ 801.6 Accounts receivable, net — 227.2 123.7 — 350.9 Deferred income tax assets 122.7 39.8 23.4 — 185.9 Other current assets 43.0 17.7 100.5 (36.6 ) 124.6 Total current assets 952.4 284.8 262.4 (36.6 ) 1,463.0 Property and equipment, net 14.9 779.4 284.8 — 1,079.1 Goodwill — 278.1 826.9 — 1,105.0 Intangible assets, net 11.9 60.9 251.9 — 324.7 Deferred income tax assets 89.4 17.5 — (51.5 ) 55.4 Other long-term assets 474.0 66.6 67.5 (386.0 ) 222.1 Intercompany receivable and investments in consolidated affiliates 1,983.6 — — (1,983.6 ) — Total assets $ 3,526.2 $ 1,487.3 $ 1,693.5 $ (2,457.7 ) $ 4,249.3 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 29.8 $ 4.4 $ 6.9 $ (17.5 ) $ 23.6 Accounts payable 9.8 32.8 23.0 — 65.6 Accrued expenses and other current liabilities 125.5 75.3 132.7 (19.1 ) 314.4 Total current liabilities 165.1 112.5 162.6 (36.6 ) 403.6 Long-term debt, net of current portion 2,690.0 81.0 415.7 (386.0 ) 2,800.7 Other long-term liabilities 40.7 12.0 139.1 (51.1 ) 140.7 Intercompany payable — 240.8 182.7 (423.5 ) — 2,895.8 446.3 900.1 (897.2 ) 3,345.0 Commitments and contingencies Redeemable noncontrolling interests — — 114.1 — 114.1 Shareholders’ equity: HealthSouth shareholders’ equity 630.4 1,041.0 519.5 (1,560.5 ) 630.4 Noncontrolling interests — — 159.8 — 159.8 Total shareholders’ equity 630.4 1,041.0 679.3 (1,560.5 ) 790.2 Total liabilities and shareholders’ equity $ 3,526.2 $ 1,487.3 $ 1,693.5 $ (2,457.7 ) $ 4,249.3 As of December 31, 2014 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 41.9 $ 1.5 $ 23.3 $ — $ 66.7 Accounts receivable, net — 202.6 120.6 — 323.2 Deferred income tax assets 125.0 39.8 23.6 — 188.4 Other current assets 30.9 15.1 81.1 (18.8 ) 108.3 Total current assets 197.8 259.0 248.6 (18.8 ) 686.6 Property and equipment, net 16.1 752.0 251.6 — 1,019.7 Goodwill — 279.6 804.4 — 1,084.0 Intangible assets, net 11.3 50.6 244.2 — 306.1 Deferred income tax assets 163.3 17.5 — (51.4 ) 129.4 Other long-term assets 461.3 42.5 64.3 (385.1 ) 183.0 Intercompany receivable and investments in consolidated affiliates 1,898.7 — — (1,898.7 ) — Total assets $ 2,748.5 $ 1,401.2 $ 1,613.1 $ (2,354.0 ) $ 3,408.8 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 27.9 $ 4.2 $ 6.2 $ (17.5 ) $ 20.8 Accounts payable 9.3 29.5 14.6 — 53.4 Accrued expenses and other current liabilities 107.1 72.6 111.7 (1.3 ) 290.1 Total current liabilities 144.3 106.3 132.5 (18.8 ) 364.3 Long-term debt, net of current portion 1,993.7 83.9 418.3 (385.1 ) 2,110.8 Other long-term liabilities 44.1 12.7 130.9 (51.4 ) 136.3 Intercompany payable — 368.7 195.5 (564.2 ) — 2,182.1 571.6 877.2 (1,019.5 ) 2,611.4 Commitments and contingencies Convertible perpetual preferred stock 93.2 — — — 93.2 Redeemable noncontrolling interests — — 84.7 — 84.7 Shareholders’ equity: HealthSouth shareholders’ equity 473.2 829.6 504.9 (1,334.5 ) 473.2 Noncontrolling interests — — 146.3 — 146.3 Total shareholders’ equity 473.2 829.6 651.2 (1,334.5 ) 619.5 Total liabilities and shareholders’ equity $ 2,748.5 $ 1,401.2 $ 1,613.1 $ (2,354.0 ) $ 3,408.8 Nine Months Ended September 30, 2015 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net cash provided by operating activities $ 13.9 $ 189.9 $ 164.0 $ 0.4 $ 368.2 Cash flows from investing activities: Purchases of property and equipment (10.0 ) (31.5 ) (43.7 ) — (85.2 ) Capitalized software costs (19.0 ) (0.4 ) (1.3 ) — (20.7 ) Acquisitions of businesses, net of cash acquired (56.6 ) — (30.5 ) — (87.1 ) Proceeds from sale of marketable securities 12.8 — — — 12.8 Purchase of restricted investments — — (6.5 ) — (6.5 ) Other 13.6 3.3 3.4 (13.0 ) 7.3 Net cash used in investing activities (59.2 ) (28.6 ) (78.6 ) (13.0 ) (179.4 ) Cash flows from financing activities: Principal borrowings under term loan facilities 125.0 — — — 125.0 Proceeds from bond issuance 1,400.0 — — — 1,400.0 Principal payments on debt, including pre-payments (545.0 ) (0.8 ) (15.5 ) 15.0 (546.3 ) Borrowings on revolving credit facility 315.0 — — — 315.0 Payments on revolving credit facility (615.0 ) — — — (615.0 ) Debt amendment and issue costs (31.3 ) — — — (31.3 ) Dividends paid on common stock (56.3 ) — — — (56.3 ) Dividends paid on convertible perpetual preferred stock (3.1 ) — — — (3.1 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (39.7 ) — (39.7 ) Other 1.8 (0.5 ) (1.5 ) (2.0 ) (2.2 ) Change in intercompany advances 199.0 (161.4 ) (37.2 ) (0.4 ) — Net cash provided by (used in) financing activities 790.1 (162.7 ) (93.9 ) 12.6 546.1 Increase (decrease) in cash and cash equivalents 744.8 (1.4 ) (8.5 ) — 734.9 Cash and cash equivalents at beginning of period 41.9 1.5 23.3 — 66.7 Cash and cash equivalents at end of period $ 786.7 $ 0.1 $ 14.8 $ — $ 801.6 Nine Months Ended September 30, 2014 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net cash provided by operating activities $ 53.5 $ 206.9 $ 114.3 $ — $ 374.7 Cash flows from investing activities: Purchases of property and equipment (11.9 ) (97.9 ) (24.1 ) — (133.9 ) Capitalized software costs (4.1 ) (1.5 ) (7.0 ) — (12.6 ) Acquisitions of businesses, net of cash acquired — — (15.9 ) — (15.9 ) Proceeds from sale of marketable securities — — 2.7 — 2.7 Purchase of restricted investments — — (2.5 ) — (2.5 ) Other 1.0 1.3 (2.4 ) — (0.1 ) Net cash used in investing activities (15.0 ) (98.1 ) (49.2 ) — (162.3 ) Cash flows from financing activities: Principal payments on debt, including pre-payments (1.5 ) (1.1 ) (3.1 ) — (5.7 ) Proceeds from bond issuance 175.0 — — — 175.0 Borrowings on revolving credit facility 65.0 — — — 65.0 Payments on revolving credit facility (110.0 ) — — — (110.0 ) Debt amendment and issuance costs (3.1 ) — — — (3.1 ) Repurchases of common stock, including fees and expenses (43.1 ) — — — (43.1 ) Dividends paid on common stock (47.4 ) — — — (47.4 ) Dividends paid on convertible perpetual preferred stock (4.7 ) — — — (4.7 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (39.6 ) — (39.6 ) Other 13.3 (1.9 ) (2.4 ) — 9.0 Change in intercompany advances 124.0 (106.6 ) (17.4 ) — — Net cash provided by (used in) financing activities 167.5 (109.6 ) (62.5 ) — (4.6 ) Increase (decrease) in cash and cash equivalents 206.0 (0.8 ) 2.6 — 207.8 Cash and cash equivalents at beginning of period 60.5 2.3 1.7 — 64.5 Cash and cash equivalents at end of period $ 266.5 $ 1.5 $ 4.3 $ — $ 272.3

Earnings per Common Share

Earnings per Common Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Earnings per Common Share	Earnings per Common Share The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Basic: Numerator: Income from continuing operations $ 67.5 $ 65.7 $ 188.6 $ 221.4 Less: Net income attributable to noncontrolling interests included in continuing operations (17.1 ) (14.7 ) (50.9 ) (44.3 ) Less: Income allocated to participating securities (0.3 ) (0.5 ) (0.9 ) (2.1 ) Less: Convertible perpetual preferred stock dividends — (1.6 ) (1.6 ) (4.7 ) Income from continuing operations attributable to HealthSouth common shareholders 50.1 48.9 135.2 170.3 Income (loss) from discontinued operations, net of tax, attributable to HealthSouth common shareholders 0.3 (0.9 ) (1.6 ) 2.8 Net income attributable to HealthSouth common shareholders $ 50.4 $ 48.0 $ 133.6 $ 173.1 Denominator: Basic weighted average common shares outstanding 90.6 86.5 89.1 86.8 Basic earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 0.56 $ 0.56 $ 1.52 $ 1.96 Discontinued operations — (0.01 ) (0.02 ) 0.03 Net income $ 0.56 $ 0.55 $ 1.50 $ 1.99 Diluted: Numerator: Income from continuing operations $ 67.5 $ 65.7 $ 188.6 $ 221.4 Less: Net income attributable to noncontrolling interests included in continuing operations (17.1 ) (14.7 ) (50.9 ) (44.3 ) Add: Interest on convertible debt, net of tax 2.4 2.3 7.0 6.8 Income from continuing operations attributable to HealthSouth common shareholders 52.8 53.3 144.7 183.9 Income (loss) from discontinued operations, net of tax, attributable to HealthSouth common shareholders 0.3 (0.9 ) (1.6 ) 2.8 Net income attributable to HealthSouth common shareholders $ 53.1 $ 52.4 $ 143.1 $ 186.7 Denominator: Diluted weighted average common shares outstanding 101.5 100.5 101.4 100.7 Diluted earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 0.52 $ 0.53 $ 1.43 $ 1.82 Discontinued operations — (0.01 ) (0.02 ) 0.03 Net income $ 0.52 $ 0.52 $ 1.41 $ 1.85 The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Basic weighted average common shares outstanding 90.6 86.5 89.1 86.8 Convertible perpetual preferred stock — 3.2 1.3 3.2 Convertible senior subordinated notes 8.4 8.2 8.3 8.1 Restricted stock awards, dilutive stock options, restricted stock units, and common stock warrants 2.5 2.6 2.7 2.6 Diluted weighted average common shares outstanding 101.5 100.5 101.4 100.7 In October 2014, February 2015, and May 2015, our board of directors declared a cash dividend of $0.21 per share that was paid in January 2015, April 2015, and July 2015, respectively. On July 16, 2015, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $0.23 per share, payable on October 15, 2015 to stockholders of record on October 1, 2015. On October 23, 2015, our board of directors declared a cash dividend of $0.23 per share, payable on January 15, 2016 to stockholders of record on January 2, 2016. As of September 30, 2015 and December 31, 2014 , accrued common stock dividends of $21.7 million and $18.6 million , respectively, were included in Accrued expenses and other current liabilities in our condensed consolidated balance sheets. Future dividend payments are subject to declaration by our board of directors. On April 22, 2015, we delivered notice of the exercise of our rights to force conversion of all outstanding shares of our Convertible perpetual preferred stock (par value of $0.10 per share and liquidation preference of $1,000 per share) pursuant to the underlying certificate of designations. The effective date of the conversion was April 23, 2015. On that date, each share of preferred stock automatically converted into 33.9905 shares of our common stock (par value of $0.01 per share). We completed the forced conversion by issuing and delivering in the aggregate 3,271,415 shares of our common stock to the registered holders of the 96,245 shares of the preferred stock outstanding and paying cash in lieu of fractional shares due to those holders. The indenture underlying our convertible notes includes antidilutive protection that requires adjustments to the number of shares of common stock issuable upon conversion and the exercise price for common stock upon the occurrence of certain events, including payment of cash dividends on our common stock after a de minimis threshold. At issuance, the convertible notes had a conversion price of $39.65 per share, which was equal to an initial conversion rate of 25.2194 shares per $1,000 principal amount of the convertible notes. The payment of dividends on our common stock has triggered and will continue to trigger, from time to time, the antidilutive adjustment provisions of the convertible notes. The current conversion price of the convertible notes is $38.08 per share, and the conversion rate is 26.2583 for each $1,000 principal amount of the convertible notes. See Note 8, Long-term Debt , Note 10, Convertible Perpetual Preferred Stock , and Note 17, Earnings per Common Share , to the consolidated financial statements accompanying the 2014 Form 10-K for additional information related to our convertible notes, common stock, common stock warrants, and convertible perpetual preferred stock.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Operating Revenues Policy	Net Operating Revenues — We derived consolidated Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Medicare 75.1 % 73.5 % 74.8 % 74.1 % Medicaid 3.4 % 2.2 % 3.0 % 1.8 % Workers’ compensation 0.8 % 1.1 % 0.9 % 1.2 % Managed care and other discount plans, including Medicare Advantage 17.4 % 18.8 % 17.8 % 18.6 % Other third-party payors 1.5 % 1.8 % 1.6 % 1.7 % Patients 0.5 % 1.1 % 0.6 % 1.0 % Other income 1.3 % 1.5 % 1.3 % 1.6 % Total 100.0 % 100.0 % 100.0 % 100.0 % We record gross service charges in our accounting records on an accrual basis using our established rates for the type of service provided to the patient. We recognize an estimated contractual allowance and an estimate of potential subsequent adjustments that may arise from post-payment and other reviews to reduce gross patient charges to the amount we estimate we will actually realize for the service rendered based upon previously agreed to rates with a payor. Our patient accounting system calculates contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital, home health, and hospice provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to HealthSouth under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. The United States Centers for Medicare and Medicaid Services (“CMS”) has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the “HHS-OIG”) or the United States Department of Justice. Therefore, we are unable to predict if or when we may be subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows. Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. We cannot predict when or how these audit programs will affect us. Inpatient Rehabilitation Revenues During the three and nine months ended September 30, 2015 and 2014 , our inpatient rehabilitation segment derived its Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Medicare 73.2 % 73.1 % 73.0 % 73.9 % Medicaid 3.0 % 2.2 % 2.6 % 1.8 % Workers’ compensation 1.0 % 1.1 % 1.1 % 1.2 % Managed care and other discount plans, including Medicare Advantage 18.9 % 19.0 % 19.2 % 18.8 % Other third-party payors 1.7 % 1.9 % 1.9 % 1.7 % Patients 0.6 % 1.1 % 0.7 % 1.0 % Other income 1.6 % 1.6 % 1.5 % 1.6 % Total 100.0 % 100.0 % 100.0 % 100.0 % Revenues recognized by our inpatient rehabilitation segment are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors that are considered and could influence the level of our reserves include the patient’s total length of stay for in-house patients, each patient’s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes, and additional reserves are provided to account for these factors. In connection with CMS approved and announced Recovery Audit Contractors (“RACs”) audits related to inpatient rehabilitation facilities (“IRFs”), we received requests in 2014 and 2013 to review certain patient files for discharges occurring from 2010 to 2014. These post-payment RAC audits are focused on medical necessity requirements for admission to IRFs rather than targeting a specific diagnosis code as in previous pre-payment audits. Medical necessity is an assessment by an independent physician of a patient’s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting. To date, the Medicare payments that are subject to these audit requests represent less than 1% of our Medicare patient discharges from 2010 to 2014, and not all of these patient file requests have resulted in payment denial determinations by the RACs. Because we have confidence in the medical judgment of both the referring and the admitting physicians who assess the treatment needs of their patients, we have appealed substantially all RAC denials arising from these audits using the same process we follow for appealing denials of certain diagnosis codes by Medicare Administrative Contractors (“MACs”) (see “Accounts Receivable and Allowance for Doubtful Accounts” below). Due to the delays announced by CMS in the related adjudication process, we believe the resolution of any claims that are subsequently denied as a result of these RAC audits could take in excess of three years. In addition, because we have limited experience with RACs in the context of post-payment reviews of this nature, we cannot provide assurance as to the future success of these disputes. As such, we make provisions for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for appealing denials of certain diagnosis codes by MACs. As the ultimate results of these audits impact our estimates of amounts determined to be due to HealthSouth under these reimbursement programs, our provision for claims that are part of this post-payment review process are recorded to Net operating revenues . See Note 1, Summary of Significant Accounting Policies , “Net Operating Revenues,” to the consolidated financial statements accompanying the 2014 Form 10-K. Home Health and Hospice Revenues The results of operations for our home health and hospice segment in 2014 included only the results of HealthSouth’s legacy hospital-based home health agencies. During the three and nine months ended September 30, 2015 and 2014 , our home health and hospice segment derived its Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Medicare 84.7 % 97.5 % 84.1 % 96.9 % Medicaid 5.7 % — % 5.7 % — % Workers’ compensation — % 0.4 % — % 0.2 % Managed care and other discount plans, including Medicare Advantage 9.6 % 1.1 % 10.0 % 1.8 % Other third-party payors — % 1.0 % 0.1 % 1.1 % Patients — % — % 0.1 % — % Total 100.0 % 100.0 % 100.0 % 100.0 % Home health and hospice revenues are earned as services are performed either on an episode of care basis, on a per visit basis, or on a daily basis, depending upon the payment terms and conditions established with each payor for services provided. Home Health Under the Medicare home health prospective payment system, we are paid by Medicare based on episodes of care. An episode of care is defined as a length of stay up to 60 days, with multiple continuous episodes allowed. A base episode payment is established by the Medicare program through federal legislation. The base episode payment can be adjusted based on each patient’s health including clinical condition, functional abilities, and service needs, as well as for the applicable geographic wage index, low utilization, patient transfers, and other factors. The services covered by the episode payment include all disciplines of care in addition to medical supplies. A portion of reimbursement from each Medicare episode is billed near the start of each episode, and cash is typically received before all services are rendered. Revenue for the episode of care is recorded over an average length of treatment period using a calendar day prorating method. The amount of revenue recognized for episodes of care which are incomplete at period end is based on the pro rata number of days in the episode which have been completed as of the period end date. As of September 30, 2015 and December 31, 2014 , the difference between the cash received from Medicare for a request for anticipated payment on episodes in progress and the associated estimated revenue was not material and was recorded in Other current liabilities in our condensed consolidated balance sheets. We are subject to certain Medicare regulations affecting outlier revenue if our patient’s care was unusually costly. Regulations require a cap on all outlier revenue at 10% of total Medicare revenue received by each provider during a cost reporting year. Management has reviewed the potential cap. Reserves recorded for the outlier cap were not material as of September 30, 2015 and December 31, 2014 . For episodic-based rates that are paid by other insurance carriers, including Medicare Advantage, we recognize revenue in a similar manner as discussed above for Medicare revenues. However, these rates can vary based upon the negotiated terms. For non-episodic-based revenue, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual allowances are recorded for the differences between our standard rates and the applicable contracted rates. Hospice Medicare revenues for hospice are recorded on an accrual basis based on the number of days a patient has been on service at amounts equal to an estimated daily or hourly payment rate. The payment rate is dependent on whether a patient is receiving routine home care, general inpatient care, continuous home care or respite care. Adjustments to Medicare revenues are recorded based on an inability to obtain appropriate billing documentation or authorizations acceptable to the payor or other reasons unrelated to credit risk. Hospice companies are subject to two specific payment limit caps under the Medicare program. One limit relates to inpatient care days that exceed 20% of the total days of hospice care provided for the year. The second limit relates to an aggregate Medicare reimbursement cap calculated by the Medicare fiscal intermediary. Currently, we do not believe we are at risk for exceeding these caps and have not recorded a reserve for these caps as of September 30, 2015 or December 31, 2014 . For non-Medicare hospice revenues, we record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients and third parties for services provided and are deducted from gross revenue to determine our net service revenue. We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered.
Accounts Receivable and Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts— We report accounts receivable at estimated net realizable amounts from services rendered from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers’ compensation programs, employers, and patients. Our accounts receivable are geographically dispersed, but a significant portion of our revenues are concentrated by type of payors. The concentration of net patient service accounts receivable by payor class, as a percentage of total net patient service accounts receivable, is as follows: September 30, 2015 December 31, 2014 Medicare 71.5 % 72.2 % Medicaid 2.8 % 1.8 % Workers' compensation 1.7 % 1.9 % Managed care and other discount plans, including Medicare Advantage 19.0 % 18.5 % Other third-party payors 3.9 % 3.8 % Patients 1.1 % 1.8 % Total 100.0 % 100.0 % While revenues and accounts receivable from the Medicare program are significant to our operations, we do not believe there are significant credit risks associated with this government agency. We do not believe there are any other significant concentrations of revenues from any particular payor that would subject us to any significant credit risks in the collection of our accounts receivable. We provide for accounts receivable that could become uncollectible by establishing an allowance to reduce the carrying value of such receivables to their estimated net realizable value. Additions to the allowance for doubtful accounts are made by means of the Provision for doubtful accounts . We write off uncollectible accounts (after exhausting collection efforts) against the allowance for doubtful accounts. Subsequent recoveries are recorded via the Provision for doubtful accounts . We estimate our allowance for doubtful accounts based on the aging of our accounts receivable, our historical collection experience for each type of payor, and other relevant factors so that the remaining receivables, net of allowances, are reflected at their estimated net realizable values. Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts for patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payor decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When we determine all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency. Accounts are written off after all collection efforts (internal and external) have been exhausted. The collection of outstanding receivables from Medicare, managed care payors, other third-party payors, and patients is our primary source of cash and is critical to our operating performance. While it is our policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where we are (1) unable to obtain verification because the patient’s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, and it takes several days, weeks, or months before qualification for such benefits is confirmed or denied, and (3) the patient is transferred to our hospital from an acute care hospital without having access to a credit card, cash, or check to pay the applicable patient responsibility amounts (i.e., deductibles and co-payments). Our primary collection risks relate to patient responsibility amounts and pre-payment claim reviews conducted by MACs. Patient responsibility amounts include accounts for which the patient was the primary payor or the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient co-payment amounts remain outstanding. Changes in the economy, such as increased unemployment rates or periods of recession, can further exacerbate our ability to collect patient responsibility amounts. For several years, under programs designated as “widespread probes,” certain of our MACs have conducted pre-payment claim reviews of our billings and denied payment for certain diagnosis codes. We dispute, or “appeal,” most of these denials, and we have historically collected approximately 69% of all amounts denied. For claims we choose to take to administrative law judge hearings, we have historically experienced an approximate 73% success rate. The resolution of these disputes can take in excess of three years, and we cannot provide assurance as to our ongoing and future success of these disputes. As such, we make provisions against these receivables in accordance with our accounting policy that necessarily considers historical collection trends of the receivables in this review process as part of our Provision for doubtful accounts . Because we do not write off receivables until all collection efforts have been exhausted, we do not write off receivables related to denied claims while they are in this review process. When the amount collected related to denied claims differs from the net amount previously recorded, these collection differences are recorded in the Provision for doubtful accounts . As a result, the timing of these denials by MACs and their subsequent collection can create volatility in our Provision for doubtful accounts . If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. Changes in general economic conditions, business office operations, payor mix, or trends in federal or state governmental and private employer healthcare coverage could affect our collection of accounts receivable, financial position, results of operations, and cash flows.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2015
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Concentration of Net Operating Revenues by Payor	We derived consolidated Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Medicare 75.1 % 73.5 % 74.8 % 74.1 % Medicaid 3.4 % 2.2 % 3.0 % 1.8 % Workers’ compensation 0.8 % 1.1 % 0.9 % 1.2 % Managed care and other discount plans, including Medicare Advantage 17.4 % 18.8 % 17.8 % 18.6 % Other third-party payors 1.5 % 1.8 % 1.6 % 1.7 % Patients 0.5 % 1.1 % 0.6 % 1.0 % Other income 1.3 % 1.5 % 1.3 % 1.6 % Total 100.0 % 100.0 % 100.0 % 100.0 %
Concentration of Net Patient Service Accounts Receivable by Payor Class	The concentration of net patient service accounts receivable by payor class, as a percentage of total net patient service accounts receivable, is as follows: September 30, 2015 December 31, 2014 Medicare 71.5 % 72.2 % Medicaid 2.8 % 1.8 % Workers' compensation 1.7 % 1.9 % Managed care and other discount plans, including Medicare Advantage 19.0 % 18.5 % Other third-party payors 3.9 % 3.8 % Patients 1.1 % 1.8 % Total 100.0 % 100.0 %
Inpatient Rehabilitation Hospital [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Concentration of Net Operating Revenues by Payor	During the three and nine months ended September 30, 2015 and 2014 , our inpatient rehabilitation segment derived its Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Medicare 73.2 % 73.1 % 73.0 % 73.9 % Medicaid 3.0 % 2.2 % 2.6 % 1.8 % Workers’ compensation 1.0 % 1.1 % 1.1 % 1.2 % Managed care and other discount plans, including Medicare Advantage 18.9 % 19.0 % 19.2 % 18.8 % Other third-party payors 1.7 % 1.9 % 1.9 % 1.7 % Patients 0.6 % 1.1 % 0.7 % 1.0 % Other income 1.6 % 1.6 % 1.5 % 1.6 % Total 100.0 % 100.0 % 100.0 % 100.0 %
Home Health and Hospice [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Concentration of Net Operating Revenues by Payor	During the three and nine months ended September 30, 2015 and 2014 , our home health and hospice segment derived its Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Medicare 84.7 % 97.5 % 84.1 % 96.9 % Medicaid 5.7 % — % 5.7 % — % Workers’ compensation — % 0.4 % — % 0.2 % Managed care and other discount plans, including Medicare Advantage 9.6 % 1.1 % 10.0 % 1.8 % Other third-party payors — % 1.0 % 0.1 % 1.1 % Patients — % — % 0.1 % — % Total 100.0 % 100.0 % 100.0 % 100.0 %

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date	The fair value of the assets acquired and liabilities assumed at the acquisition dates for the inpatient rehabilitation transactions completed in 2015 were as follows (in millions): Total current assets $ 10.1 Property and equipment, net 42.7 Identifiable intangible assets: Noncompete agreements (useful lives of 2 to 3 years) 0.1 Trade names (useful life of 20 years) 0.8 Certificates of need (useful lives of 20 years) 8.8 Licenses (useful life of 20 years) 0.2 Goodwill 0.7 Total assets acquired 63.4 Total liabilities assumed (2.7 ) Net assets acquired $ 60.7 The fair value of the assets acquired at the acquisition date for the home health and hospice transactions completed in 2015 were as follows (in millions): Property and equipment $ 0.1 Identifiable intangible assets: Noncompete agreements (useful lives of 2 to 5 years) 1.3 Trade names (useful lives of 1 year) 0.5 Certificates of need (useful lives of 10 years) 4.9 Licenses (useful lives of 10 years) 3.6 Goodwill 20.3 Total assets acquired 30.7 Total liabilities assumed (0.2 ) Net assets acquired $ 30.5
Schedule of Noncash or Part Noncash Acquisitions	Information regarding the net cash paid for all home health and hospice acquisitions during each period presented is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Fair value of assets acquired $ 1.9 $ — $ 10.4 $ — Goodwill 7.5 — 20.3 — Fair value of liabilities assumed (0.1 ) — (0.2 ) — Net cash paid for acquisitions $ 9.3 $ — $ 30.5 $ — Information regarding the net cash paid for all inpatient rehabilitation acquisitions during each period presented is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Fair value of assets acquired $ — $ — $ 62.8 $ 52.0 Goodwill — — 0.7 34.8 Fair value of liabilities assumed — — (2.7 ) (21.9 ) Fair value of noncontrolling interest owned by joint venture partner — — (4.2 ) (14.0 ) Fair value of equity interest prior to acquisition — — — (35.0 ) Net cash paid for acquisitions $ — $ — $ 56.6 $ 15.9
Summary of Actual and Pro Forma Results of Operations for Acquisitions	The following table summarizes the results of operations of the above mentioned transactions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2014 (in millions): Net Operating Revenues Net Income Attributable to HealthSouth Acquired entities only: Actual from acquisition date to September 30, 2015* $ 40.8 $ 0.6 Combined entity: Supplemental pro forma from 07/01/2015-09/30/2015 778.9 50.7 Combined entity: Supplemental pro forma from 07/01/2014-09/30/2014 621.5 51.2 Combined entity: Supplemental pro forma from 01/01/2015-09/30/2015 2,316.3 136.6 Combined entity: Supplemental pro forma from 01/01/2014-09/30/2014 1,863.9 181.3 * Savannah - includes operating results from April 1, 2015 through September 30, 2015 Cardinal Hill - includes operating results from May 1, 2015 through September 30, 2015 Integrity - includes operating results from March 3, 2015 through September 30, 2015 Harvey - includes operating results from April 15, 2015 through September 30, 2015 Heritage - includes operating results from May 1, 2015 through September 30, 2015 Alliance - includes operating results from June 4, 2015 through September 30, 2015 Southern Utah - includes operating results from July 1, 2015 through September 30, 2015 ORS - includes operating results from July 13, 2015 through September 30, 2015

Investments in and Advances t23

Investments in and Advances to Nonconsolidated Affiliates (Tables)	9 Months Ended
	Sep. 30, 2015
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Abstract]
Schedule of Combined Results of Operations of Equity Method Affiliates	The following summarizes the combined results of operations of our equity method affiliates (on a 100% basis, in millions): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Net operating revenues $ 9.2 $ 7.8 $ 26.3 $ 44.1 Operating expenses (4.0 ) (3.3 ) (11.7 ) (22.7 ) Income from continuing operations, net of tax 5.1 4.2 13.8 28.2 Net income 5.1 4.2 13.8 28.2

Long-term Debt (Tables)

Long-term Debt (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Outstanding Long-term Debt	Our long-term debt outstanding consists of the following (in millions): September 30, 2015 December 31, 2014 Credit Agreement— Advances under revolving credit facility $ 25.0 $ 325.0 Term loan facilities 320.0 450.0 Bonds payable— 8.125% Senior Notes due 2020 — 287.0 7.75% Senior Notes due 2022 227.0 227.1 5.125% Senior Notes due 2023 300.0 — 5.75% Senior Notes due 2024 1,215.2 456.2 5.75% Senior Notes due 2025 350.0 — 2.0% Convertible Senior Subordinated Notes due 2043 264.7 258.0 Other notes payable 40.3 41.6 Capital lease obligations 82.1 86.7 2,824.3 2,131.6 Less: Current portion (23.6 ) (20.8 ) Long-term debt, net of current portion $ 2,800.7 $ 2,110.8
Schedule of Debt Maturities	The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions): Face Amount Net Amount October 1 through December 31, 2015 $ 3.4 $ 3.4 2016 27.3 27.3 2017 25.6 25.6 2018 25.0 25.0 2019 27.8 27.8 2020 603.0 547.7 Thereafter 2,151.4 2,167.5 Total $ 2,863.5 $ 2,824.3
Debt Instrument Redemption	We may redeem the 2025 Notes, in whole or in part, at any time on or after September 15, 2020 at the redemption prices set forth below: Period Redemption Price* 2020 102.875 % 2021 101.917 % 2022 100.958 % 2023 and thereafter 100.000 % * Expressed in percentage of principal amount We may redeem the 2023 Notes, in whole or in part, at any time on or after March 15, 2018 at the redemption prices set forth below: Period Redemption Price* 2018 103.844 % 2019 102.563 % 2020 101.281 % 2021 and thereafter 100.000 % * Expressed in percentage of principal amount

Redeemable Noncontrolling Int25

Redeemable Noncontrolling Interests (Tables)	9 Months Ended
	Sep. 30, 2015
Redeemable Noncontrolling Interest [Line Items]
Redeemable Noncontrolling Interest	The following is a summary of the activity related to our Redeemable noncontrolling interests during the nine months ended September 30, 2015 and 2014 (in millions): Nine Months Ended September 30, 2015 2014 Balance at beginning of period $ 84.7 $ 13.5 Net income attributable to noncontrolling interests 10.1 5.4 Distributions declared (5.6 ) (6.7 ) Change in fair value 24.9 — Balance at end of period $ 114.1 $ 12.2
Reconciliation of Noncontrolling Interests	The following table reconciles the net income attributable to nonredeemable Noncontrolling interests , as recorded in the shareholders’ equity section of the condensed consolidated balance sheets, and the net income attributable to Redeemable noncontrolling interests , as recorded in the mezzanine section of the condensed consolidated balance sheets, to the Net income attributable to noncontrolling interests presented in the condensed consolidated statements of operations for the three and nine months ended September 30, 2015 and 2014 (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Net income attributable to nonredeemable noncontrolling interests $ 13.4 $ 12.9 $ 40.8 $ 38.9 Net income attributable to redeemable noncontrolling interests 3.7 1.8 10.1 5.4 Net income attributable to noncontrolling interests $ 17.1 $ 14.7 $ 50.9 $ 44.3

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis	Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): Fair Value Measurements at Reporting Date Using As of September 30, 2015 Fair Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Valuation Technique (1) Other current assets: Current portion of restricted marketable securities $ 16.6 $ — $ 16.6 $ — M Other long-term assets: Restricted marketable securities 39.4 — 39.4 — M Redeemable noncontrolling interests 114.1 — — 114.1 I As of December 31, 2014 Other current assets: Current portion of restricted marketable securities $ 4.6 $ — $ 4.6 $ — M Other long-term assets: Option to purchase SCA stock 9.9 — — 9.9 M Restricted marketable securities 45.9 — 45.9 — M Redeemable noncontrolling interests 84.7 — — 84.7 I (1) The three valuation techniques are: market approach (M), cost approach (C), and income approach (I).
Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments	The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions): As of September 30, 2015 As of December 31, 2014 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Long-term debt: Advances under revolving credit facility $ 25.0 $ 25.0 $ 325.0 $ 325.0 Term loan facilities 320.0 320.0 450.0 450.0 8.125% Senior Notes due 2020 — — 287.0 302.5 7.75% Senior Notes due 2022 227.0 235.9 227.1 240.7 5.125% Senior Notes due 2023 300.0 289.8 — — 5.75% Senior Notes due 2024 1,215.2 1,182.0 456.2 471.4 5.75% Senior Notes due 2025 350.0 340.4 — — 2.00% Convertible Senior Subordinated Notes due 2043 264.7 362.4 258.0 358.4 Other notes payable 40.3 40.3 41.6 41.6 Financial commitments: Letters of credit — 34.2 — 31.8

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Summary of Income Tax Contingencies	A reconciliation of the beginning and ending liability for unrecognized tax benefits is as follows (in millions): Gross Unrecognized Income Tax Benefits Balance at December 31, 2014 $ 0.9 Gross amount of increases in unrecognized tax benefits related to prior periods 1.5 Balance at September 30, 2015 $ 2.4

Segment Reporting Segment Rep28

Segment Reporting Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Selected financial information for our reportable segments is as follows (in millions): Inpatient Rehabilitation Home Health and Hospice Three Months Ended September 30, Nine Months Ended September 30, Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 2015 2014 2015 2014 Net operating revenues $ 651.6 $ 589.9 $ 1,927.2 $ 1,771.5 $ 127.0 $ 7.0 $ 356.4 $ 21.0 Less: Provision for doubtful accounts (10.2 ) (8.1 ) (31.4 ) (24.7 ) (0.5 ) (0.1 ) (1.8 ) (0.3 ) Net operating revenues less provision for doubtful accounts 641.4 581.8 1,895.8 1,746.8 126.5 6.9 354.6 20.7 Operating expenses: Inpatient rehabilitation: Salaries and benefits 326.8 285.0 950.8 846.1 — — — — Other operating expenses 95.8 86.1 284.5 252.8 — — — — Supplies 28.9 26.5 88.6 81.7 — — — — Occupancy costs 10.6 10.2 31.7 30.8 — — — — Home health and hospice: Cost of services sold (excluding depreciation and amortization) — — — — 61.7 4.1 171.8 12.5 Support and overhead costs — — — — 42.6 1.7 121.7 5.1 462.1 407.8 1,355.6 1,211.4 104.3 5.8 293.5 17.6 Other income (0.1 ) (0.2 ) (1.0 ) (2.9 ) — — — — Equity in net income of nonconsolidated affiliates (2.4 ) (1.9 ) (6.3 ) (8.8 ) — — — — Noncontrolling interests 15.6 14.6 46.4 44.0 1.5 0.1 4.5 0.3 Segment Adjusted EBITDA $ 166.2 $ 161.5 $ 501.1 $ 503.1 $ 20.7 $ 1.0 $ 56.6 $ 2.8 Capital expenditures $ 43.8 $ 46.1 $ 103.2 $ 146.6 $ 0.5 $ — $ 2.7 $ —
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	Inpatient Rehabilitation Home Health and Hospice HealthSouth Consolidated As of September 30, 2015 Total assets $ 3,419.4 $ 894.2 $ 4,249.3 Investments in and advances to nonconsolidated affiliates 11.1 — 11.1 As of December 31, 2014 Total assets $ 2,596.8 $ 876.3 $ 3,408.8 Investments in and advances to nonconsolidated affiliates 9.4 — 9.4 September 30, 2015 December 31, 2014 Total assets for reportable segments $ 4,313.6 $ 3,473.1 Reclassification of noncurrent deferred income tax liabilities to net noncurrent deferred income tax assets (64.3 ) (64.3 ) Total consolidated assets $ 4,249.3 $ 3,408.8
Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense [Table Text Block]	Segment reconciliations (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Total segment Adjusted EBITDA $ 186.9 $ 162.5 $ 557.7 $ 505.9 General and administrative expenses (30.6 ) (27.5 ) (97.3 ) (88.4 ) Depreciation and amortization (33.7 ) (27.4 ) (98.3 ) (80.2 ) Loss on disposal or impairment of assets (0.9 ) (2.7 ) (0.2 ) (5.7 ) Government, class action, and related settlements — — (8.0 ) 0.8 Professional fees - accounting, tax, and legal (0.4 ) (4.0 ) (2.7 ) (7.6 ) Loss on early extinguishment of debt — — (20.0 ) — Interest expense and amortization of debt discounts and fees (35.6 ) (27.8 ) (98.3 ) (83.5 ) Gain on consolidation of former equity method hospital — — — 27.2 Net income attributable to noncontrolling interests 17.1 14.7 50.9 44.3 Gain related to SCA equity interest 0.6 — 3.2 — Income from continuing operations before income tax expense $ 103.4 $ 87.8 $ 287.0 $ 312.8
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	Additional detail regarding the revenues of our operating segments by service line follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Inpatient rehabilitation: Inpatient $ 625.1 $ 563.7 $ 1,850.4 $ 1,691.6 Outpatient and other 26.5 26.2 76.8 79.9 Total inpatient rehabilitation 651.6 589.9 1,927.2 1,771.5 Home health and hospice: Home health 118.3 7.0 333.7 21.0 Hospice 8.7 — 22.7 — Total home health and hospice 127.0 7.0 356.4 21.0 Total net operating revenues $ 778.6 $ 596.9 $ 2,283.6 $ 1,792.5

Condensed Consolidating Finan29

Condensed Consolidating Financial Information (Tables)	9 Months Ended
	Sep. 30, 2015
Condensed Consolidating Financial Information [Abstract]
Condensed Consolidating Statement of Operations	Three Months Ended September 30, 2015 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 4.3 $ 468.6 $ 331.7 $ (26.0 ) $ 778.6 Less: Provision for doubtful accounts — (7.7 ) (3.0 ) — (10.7 ) Net operating revenues less provision for doubtful accounts 4.3 460.9 328.7 (26.0 ) 767.9 Operating expenses: Salaries and benefits 14.7 218.9 187.7 (4.2 ) 417.1 Other operating expenses 6.5 68.2 42.0 (10.0 ) 106.7 Occupancy costs 1.1 16.9 6.3 (11.8 ) 12.5 Supplies — 20.2 10.8 — 31.0 General and administrative expenses 27.8 — 2.8 — 30.6 Depreciation and amortization 2.6 20.0 11.1 — 33.7 Professional fees—accounting, tax, and legal 0.4 — — — 0.4 Total operating expenses 53.1 344.2 260.7 (26.0 ) 632.0 Interest expense and amortization of debt discounts and fees 33.4 2.1 2.7 (2.6 ) 35.6 Other income (2.5 ) (0.1 ) (0.7 ) 2.6 (0.7 ) Equity in net income of nonconsolidated affiliates — (2.4 ) — — (2.4 ) Equity in net income of consolidated affiliates (80.4 ) (9.2 ) — 89.6 — Management fees (29.2 ) 22.2 7.0 — — Income from continuing operations before income tax (benefit) expense 29.9 104.1 59.0 (89.6 ) 103.4 Provision for income tax (benefit) expense (20.5 ) 39.5 16.9 — 35.9 Income from continuing operations 50.4 64.6 42.1 (89.6 ) 67.5 Income from discontinued operations, net of tax 0.3 — — — 0.3 Net income 50.7 64.6 42.1 (89.6 ) 67.8 Less: Net income attributable to noncontrolling interests — — (17.1 ) — (17.1 ) Net income attributable to HealthSouth $ 50.7 $ 64.6 $ 25.0 $ (89.6 ) $ 50.7 Comprehensive income $ 49.9 $ 64.6 $ 42.1 $ (89.6 ) $ 67.0 Comprehensive income attributable to HealthSouth $ 49.9 $ 64.6 $ 25.0 $ (89.6 ) $ 49.9 Three Months Ended September 30, 2014 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 4.0 $ 424.5 $ 191.2 $ (22.8 ) $ 596.9 Less: Provision for doubtful accounts — (5.7 ) (2.5 ) — (8.2 ) Net operating revenues less provision for doubtful accounts 4.0 418.8 188.7 (22.8 ) 588.7 Operating expenses: Salaries and benefits 4.1 197.9 91.8 (3.8 ) 290.0 Other operating expenses 5.0 62.0 31.8 (9.4 ) 89.4 Occupancy costs 1.1 14.5 4.3 (9.6 ) 10.3 Supplies 0.1 18.6 7.9 — 26.6 General and administrative expenses 27.5 — — — 27.5 Depreciation and amortization 2.3 18.2 6.9 — 27.4 Professional fees—accounting, tax, and legal 4.0 — — — 4.0 Total operating expenses 44.1 311.2 142.7 (22.8 ) 475.2 Interest expense and amortization of debt discounts and fees 25.7 1.7 0.7 (0.3 ) 27.8 Other income 0.1 — (0.6 ) 0.3 (0.2 ) Equity in net income of nonconsolidated affiliates — (1.9 ) — — (1.9 ) Equity in net income of consolidated affiliates (62.6 ) (7.2 ) — 69.8 — Management fees (26.8 ) 20.4 6.4 — — Income from continuing operations before income tax (benefit) expense 23.5 94.6 39.5 (69.8 ) 87.8 Provision for income tax (benefit) expense (27.5 ) 39.2 10.4 — 22.1 Income from continuing operations 51.0 55.4 29.1 (69.8 ) 65.7 Loss from discontinued operations, net of tax (0.9 ) — — — (0.9 ) Net income 50.1 55.4 29.1 (69.8 ) 64.8 Less: Net income attributable to noncontrolling interests — — (14.7 ) — (14.7 ) Net income attributable to HealthSouth $ 50.1 $ 55.4 $ 14.4 $ (69.8 ) $ 50.1 Comprehensive income $ 50.0 $ 55.4 $ 29.1 $ (69.8 ) $ 64.7 Comprehensive income attributable to HealthSouth $ 50.0 $ 55.4 $ 14.4 $ (69.8 ) $ 50.0 Nine Months Ended September 30, 2015 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 14.7 $ 1,394.8 $ 950.5 $ (76.4 ) $ 2,283.6 Less: Provision for doubtful accounts — (25.0 ) (8.2 ) — (33.2 ) Net operating revenues less provision for doubtful accounts 14.7 1,369.8 942.3 (76.4 ) 2,250.4 Operating expenses: Salaries and benefits 35.0 647.0 534.5 (12.5 ) 1,204.0 Other operating expenses 22.7 199.6 122.4 (30.6 ) 314.1 Occupancy costs 3.2 48.6 18.6 (33.3 ) 37.1 Supplies — 62.2 31.9 — 94.1 General and administrative expenses 93.6 — 3.7 — 97.3 Depreciation and amortization 7.3 58.7 32.3 — 98.3 Government, class action, and related settlements 8.0 — — — 8.0 Professional fees—accounting, tax, and legal 2.7 — — — 2.7 Total operating expenses 172.5 1,016.1 743.4 (76.4 ) 1,855.6 Loss on early extinguishment of debt 20.0 — — — 20.0 Interest expense and amortization of debt discounts and fees 91.0 6.6 8.2 (7.5 ) 98.3 Other income (9.6 ) (0.2 ) (1.9 ) 7.5 (4.2 ) Equity in net income of nonconsolidated affiliates — (6.3 ) — — (6.3 ) Equity in net income of consolidated affiliates (241.0 ) (25.4 ) — 266.4 — Management fees (87.0 ) 66.2 20.8 — — Income from continuing operations before income tax (benefit) expense 68.8 312.8 171.8 (266.4 ) 287.0 Provision for income tax (benefit) expense (68.9 ) 118.9 48.4 — 98.4 Income from continuing operations 137.7 193.9 123.4 (266.4 ) 188.6 Loss from discontinued operations, net of tax (1.6 ) — — — (1.6 ) Net income 136.1 193.9 123.4 (266.4 ) 187.0 Less: Net income attributable to noncontrolling interests — — (50.9 ) — (50.9 ) Net income attributable to HealthSouth $ 136.1 $ 193.9 $ 72.5 $ (266.4 ) $ 136.1 Comprehensive income $ 135.5 $ 193.9 $ 123.4 $ (266.4 ) $ 186.4 Comprehensive income attributable to HealthSouth $ 135.5 $ 193.9 $ 72.5 $ (266.4 ) $ 135.5 Nine Months Ended September 30, 2014 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 11.5 $ 1,286.4 $ 561.7 $ (67.1 ) $ 1,792.5 Less: Provision for doubtful accounts — (17.6 ) (7.4 ) — (25.0 ) Net operating revenues less provision for doubtful accounts 11.5 1,268.8 554.3 (67.1 ) 1,767.5 Operating expenses: Salaries and benefits 15.9 590.2 266.6 (11.3 ) 861.4 Other operating expenses 15.0 182.1 90.0 (26.9 ) 260.2 Occupancy costs 3.1 43.4 13.5 (28.9 ) 31.1 Supplies — 57.9 24.1 — 82.0 General and administrative expenses 88.4 — — — 88.4 Depreciation and amortization 7.4 54.1 18.7 — 80.2 Government, class action, and related settlements (0.8 ) — — — (0.8 ) Professional fees—accounting, tax, and legal 7.6 — — — 7.6 Total operating expenses 136.6 927.7 412.9 (67.1 ) 1,410.1 Interest expense and amortization of debt discounts and fees 76.3 5.9 2.1 (0.8 ) 83.5 Other income (0.3 ) (28.4 ) (2.2 ) 0.8 (30.1 ) Equity in net income of nonconsolidated affiliates — (8.8 ) — — (8.8 ) Equity in net income of consolidated affiliates (233.9 ) (21.3 ) — 255.2 — Management fees (80.7 ) 61.6 19.1 — — Income from continuing operations before income tax (benefit) expense 113.5 332.1 122.4 (255.2 ) 312.8 Provision for income tax (benefit) expense (63.5 ) 122.0 32.9 — 91.4 Income from continuing operations 177.0 210.1 89.5 (255.2 ) 221.4 Income (loss) from discontinued operations, net of tax 2.9 — (0.1 ) — 2.8 Net income 179.9 210.1 89.4 (255.2 ) 224.2 Less: Net income attributable to noncontrolling interests — — (44.3 ) — (44.3 ) Net income attributable to HealthSouth $ 179.9 $ 210.1 $ 45.1 $ (255.2 ) $ 179.9 Comprehensive income $ 179.9 $ 210.1 $ 89.4 $ (255.2 ) $ 224.2 Comprehensive income attributable to HealthSouth $ 179.9 $ 210.1 $ 45.1 $ (255.2 ) $ 179.9
Condensed Consolidating Balance Sheet	As of September 30, 2015 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 786.7 $ 0.1 $ 14.8 $ — $ 801.6 Accounts receivable, net — 227.2 123.7 — 350.9 Deferred income tax assets 122.7 39.8 23.4 — 185.9 Other current assets 43.0 17.7 100.5 (36.6 ) 124.6 Total current assets 952.4 284.8 262.4 (36.6 ) 1,463.0 Property and equipment, net 14.9 779.4 284.8 — 1,079.1 Goodwill — 278.1 826.9 — 1,105.0 Intangible assets, net 11.9 60.9 251.9 — 324.7 Deferred income tax assets 89.4 17.5 — (51.5 ) 55.4 Other long-term assets 474.0 66.6 67.5 (386.0 ) 222.1 Intercompany receivable and investments in consolidated affiliates 1,983.6 — — (1,983.6 ) — Total assets $ 3,526.2 $ 1,487.3 $ 1,693.5 $ (2,457.7 ) $ 4,249.3 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 29.8 $ 4.4 $ 6.9 $ (17.5 ) $ 23.6 Accounts payable 9.8 32.8 23.0 — 65.6 Accrued expenses and other current liabilities 125.5 75.3 132.7 (19.1 ) 314.4 Total current liabilities 165.1 112.5 162.6 (36.6 ) 403.6 Long-term debt, net of current portion 2,690.0 81.0 415.7 (386.0 ) 2,800.7 Other long-term liabilities 40.7 12.0 139.1 (51.1 ) 140.7 Intercompany payable — 240.8 182.7 (423.5 ) — 2,895.8 446.3 900.1 (897.2 ) 3,345.0 Commitments and contingencies Redeemable noncontrolling interests — — 114.1 — 114.1 Shareholders’ equity: HealthSouth shareholders’ equity 630.4 1,041.0 519.5 (1,560.5 ) 630.4 Noncontrolling interests — — 159.8 — 159.8 Total shareholders’ equity 630.4 1,041.0 679.3 (1,560.5 ) 790.2 Total liabilities and shareholders’ equity $ 3,526.2 $ 1,487.3 $ 1,693.5 $ (2,457.7 ) $ 4,249.3 As of December 31, 2014 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 41.9 $ 1.5 $ 23.3 $ — $ 66.7 Accounts receivable, net — 202.6 120.6 — 323.2 Deferred income tax assets 125.0 39.8 23.6 — 188.4 Other current assets 30.9 15.1 81.1 (18.8 ) 108.3 Total current assets 197.8 259.0 248.6 (18.8 ) 686.6 Property and equipment, net 16.1 752.0 251.6 — 1,019.7 Goodwill — 279.6 804.4 — 1,084.0 Intangible assets, net 11.3 50.6 244.2 — 306.1 Deferred income tax assets 163.3 17.5 — (51.4 ) 129.4 Other long-term assets 461.3 42.5 64.3 (385.1 ) 183.0 Intercompany receivable and investments in consolidated affiliates 1,898.7 — — (1,898.7 ) — Total assets $ 2,748.5 $ 1,401.2 $ 1,613.1 $ (2,354.0 ) $ 3,408.8 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 27.9 $ 4.2 $ 6.2 $ (17.5 ) $ 20.8 Accounts payable 9.3 29.5 14.6 — 53.4 Accrued expenses and other current liabilities 107.1 72.6 111.7 (1.3 ) 290.1 Total current liabilities 144.3 106.3 132.5 (18.8 ) 364.3 Long-term debt, net of current portion 1,993.7 83.9 418.3 (385.1 ) 2,110.8 Other long-term liabilities 44.1 12.7 130.9 (51.4 ) 136.3 Intercompany payable — 368.7 195.5 (564.2 ) — 2,182.1 571.6 877.2 (1,019.5 ) 2,611.4 Commitments and contingencies Convertible perpetual preferred stock 93.2 — — — 93.2 Redeemable noncontrolling interests — — 84.7 — 84.7 Shareholders’ equity: HealthSouth shareholders’ equity 473.2 829.6 504.9 (1,334.5 ) 473.2 Noncontrolling interests — — 146.3 — 146.3 Total shareholders’ equity 473.2 829.6 651.2 (1,334.5 ) 619.5 Total liabilities and shareholders’ equity $ 2,748.5 $ 1,401.2 $ 1,613.1 $ (2,354.0 ) $ 3,408.8
Condensed Consolidating Statement of Cash Flows	Nine Months Ended September 30, 2015 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net cash provided by operating activities $ 13.9 $ 189.9 $ 164.0 $ 0.4 $ 368.2 Cash flows from investing activities: Purchases of property and equipment (10.0 ) (31.5 ) (43.7 ) — (85.2 ) Capitalized software costs (19.0 ) (0.4 ) (1.3 ) — (20.7 ) Acquisitions of businesses, net of cash acquired (56.6 ) — (30.5 ) — (87.1 ) Proceeds from sale of marketable securities 12.8 — — — 12.8 Purchase of restricted investments — — (6.5 ) — (6.5 ) Other 13.6 3.3 3.4 (13.0 ) 7.3 Net cash used in investing activities (59.2 ) (28.6 ) (78.6 ) (13.0 ) (179.4 ) Cash flows from financing activities: Principal borrowings under term loan facilities 125.0 — — — 125.0 Proceeds from bond issuance 1,400.0 — — — 1,400.0 Principal payments on debt, including pre-payments (545.0 ) (0.8 ) (15.5 ) 15.0 (546.3 ) Borrowings on revolving credit facility 315.0 — — — 315.0 Payments on revolving credit facility (615.0 ) — — — (615.0 ) Debt amendment and issue costs (31.3 ) — — — (31.3 ) Dividends paid on common stock (56.3 ) — — — (56.3 ) Dividends paid on convertible perpetual preferred stock (3.1 ) — — — (3.1 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (39.7 ) — (39.7 ) Other 1.8 (0.5 ) (1.5 ) (2.0 ) (2.2 ) Change in intercompany advances 199.0 (161.4 ) (37.2 ) (0.4 ) — Net cash provided by (used in) financing activities 790.1 (162.7 ) (93.9 ) 12.6 546.1 Increase (decrease) in cash and cash equivalents 744.8 (1.4 ) (8.5 ) — 734.9 Cash and cash equivalents at beginning of period 41.9 1.5 23.3 — 66.7 Cash and cash equivalents at end of period $ 786.7 $ 0.1 $ 14.8 $ — $ 801.6 Nine Months Ended September 30, 2014 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net cash provided by operating activities $ 53.5 $ 206.9 $ 114.3 $ — $ 374.7 Cash flows from investing activities: Purchases of property and equipment (11.9 ) (97.9 ) (24.1 ) — (133.9 ) Capitalized software costs (4.1 ) (1.5 ) (7.0 ) — (12.6 ) Acquisitions of businesses, net of cash acquired — — (15.9 ) — (15.9 ) Proceeds from sale of marketable securities — — 2.7 — 2.7 Purchase of restricted investments — — (2.5 ) — (2.5 ) Other 1.0 1.3 (2.4 ) — (0.1 ) Net cash used in investing activities (15.0 ) (98.1 ) (49.2 ) — (162.3 ) Cash flows from financing activities: Principal payments on debt, including pre-payments (1.5 ) (1.1 ) (3.1 ) — (5.7 ) Proceeds from bond issuance 175.0 — — — 175.0 Borrowings on revolving credit facility 65.0 — — — 65.0 Payments on revolving credit facility (110.0 ) — — — (110.0 ) Debt amendment and issuance costs (3.1 ) — — — (3.1 ) Repurchases of common stock, including fees and expenses (43.1 ) — — — (43.1 ) Dividends paid on common stock (47.4 ) — — — (47.4 ) Dividends paid on convertible perpetual preferred stock (4.7 ) — — — (4.7 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (39.6 ) — (39.6 ) Other 13.3 (1.9 ) (2.4 ) — 9.0 Change in intercompany advances 124.0 (106.6 ) (17.4 ) — — Net cash provided by (used in) financing activities 167.5 (109.6 ) (62.5 ) — (4.6 ) Increase (decrease) in cash and cash equivalents 206.0 (0.8 ) 2.6 — 207.8 Cash and cash equivalents at beginning of period 60.5 2.3 1.7 — 64.5 Cash and cash equivalents at end of period $ 266.5 $ 1.5 $ 4.3 $ — $ 272.3

Earnings per Common Share (Tabl

Earnings per Common Share (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Common Share	The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Basic: Numerator: Income from continuing operations $ 67.5 $ 65.7 $ 188.6 $ 221.4 Less: Net income attributable to noncontrolling interests included in continuing operations (17.1 ) (14.7 ) (50.9 ) (44.3 ) Less: Income allocated to participating securities (0.3 ) (0.5 ) (0.9 ) (2.1 ) Less: Convertible perpetual preferred stock dividends — (1.6 ) (1.6 ) (4.7 ) Income from continuing operations attributable to HealthSouth common shareholders 50.1 48.9 135.2 170.3 Income (loss) from discontinued operations, net of tax, attributable to HealthSouth common shareholders 0.3 (0.9 ) (1.6 ) 2.8 Net income attributable to HealthSouth common shareholders $ 50.4 $ 48.0 $ 133.6 $ 173.1 Denominator: Basic weighted average common shares outstanding 90.6 86.5 89.1 86.8 Basic earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 0.56 $ 0.56 $ 1.52 $ 1.96 Discontinued operations — (0.01 ) (0.02 ) 0.03 Net income $ 0.56 $ 0.55 $ 1.50 $ 1.99 Diluted: Numerator: Income from continuing operations $ 67.5 $ 65.7 $ 188.6 $ 221.4 Less: Net income attributable to noncontrolling interests included in continuing operations (17.1 ) (14.7 ) (50.9 ) (44.3 ) Add: Interest on convertible debt, net of tax 2.4 2.3 7.0 6.8 Income from continuing operations attributable to HealthSouth common shareholders 52.8 53.3 144.7 183.9 Income (loss) from discontinued operations, net of tax, attributable to HealthSouth common shareholders 0.3 (0.9 ) (1.6 ) 2.8 Net income attributable to HealthSouth common shareholders $ 53.1 $ 52.4 $ 143.1 $ 186.7 Denominator: Diluted weighted average common shares outstanding 101.5 100.5 101.4 100.7 Diluted earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 0.52 $ 0.53 $ 1.43 $ 1.82 Discontinued operations — (0.01 ) (0.02 ) 0.03 Net income $ 0.52 $ 0.52 $ 1.41 $ 1.85
Reconciliation of Weighted Average Number of Shares Outstanding	The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Basic weighted average common shares outstanding 90.6 86.5 89.1 86.8 Convertible perpetual preferred stock — 3.2 1.3 3.2 Convertible senior subordinated notes 8.4 8.2 8.3 8.1 Restricted stock awards, dilutive stock options, restricted stock units, and common stock warrants 2.5 2.6 2.7 2.6 Diluted weighted average common shares outstanding 101.5 100.5 101.4 100.7

Basis of Presentation - Table 1

Basis of Presentation - Table 1 (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Basis of Presentation [Abstract]
Medicare	75.10%	73.50%	74.80%	74.10%
Medicaid	3.40%	2.20%	3.00%	1.80%
Workers’ compensation	0.80%	1.10%	0.90%	1.20%
Managed care and other discount plans, including Medicare Advantage	17.40%	18.80%	17.80%	18.60%
Other third-party payors	1.50%	1.80%	1.60%	1.70%
Patients	0.50%	1.10%	0.60%	1.00%
Other income	1.30%	1.50%	1.30%	1.60%
Total	100.00%	100.00%	100.00%	100.00%

Basis of Presentation Basis of

Basis of Presentation Basis of Presentation - Table 2 (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Medicare	75.10%	73.50%	74.80%	74.10%
Medicaid	3.40%	2.20%	3.00%	1.80%
Workers’ compensation	0.80%	1.10%	0.90%	1.20%
Managed care and other discount plans, including Medicare Advantage	17.40%	18.80%	17.80%	18.60%
Other third-party payors	1.50%	1.80%	1.60%	1.70%
Patients	0.50%	1.10%	0.60%	1.00%
Other income	1.30%	1.50%	1.30%	1.60%
Total	100.00%	100.00%	100.00%	100.00%
Inpatient Rehabilitation Hospital [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Medicare	73.20%	73.10%	73.00%	73.90%
Medicaid	3.00%	2.20%	2.60%	1.80%
Workers’ compensation	1.00%	1.10%	1.10%	1.20%
Managed care and other discount plans, including Medicare Advantage	18.90%	19.00%	19.20%	18.80%
Other third-party payors	1.70%	1.90%	1.90%	1.70%
Patients	0.60%	1.10%	0.70%	1.00%
Other income	1.60%	1.60%	1.50%	1.60%
Total	100.00%	100.00%	100.00%	100.00%

Basis of Presentation Basis o33

Basis of Presentation Basis of Presentation - Table 3 (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Medicare	75.10%	73.50%	74.80%	74.10%
Medicaid	3.40%	2.20%	3.00%	1.80%
Workers’ compensation	0.80%	1.10%	0.90%	1.20%
Managed care and other discount plans, including Medicare Advantage	17.40%	18.80%	17.80%	18.60%
Other third-party payors	1.50%	1.80%	1.60%	1.70%
Patients	0.50%	1.10%	0.60%	1.00%
Total	100.00%	100.00%	100.00%	100.00%
Home Health and Hospice [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Medicare	84.70%	97.50%	84.10%	96.90%
Medicaid	5.70%	0.00%	5.70%	0.00%
Workers’ compensation	0.00%	0.40%	0.00%	0.20%
Managed care and other discount plans, including Medicare Advantage	9.60%	1.10%	10.00%	1.80%
Other third-party payors	0.00%	1.00%	0.10%	1.10%
Patients	0.00%	0.00%	0.10%	0.00%
Total	100.00%	100.00%	100.00%	100.00%

Basis of Presentation Basis o34

Basis of Presentation Basis of Presentation - Table 4 (Details)	Sep. 30, 2015	Dec. 31, 2014
Concentration Of Net Patient Service Accounts Receivable By Payor Class [Abstract]
Medicare	71.50%	72.20%
Medicaid	2.80%	1.80%
Workers compensation	1.70%	1.90%
Managed care and other discount plans, including Medicare Advantage	19.00%	18.50%
Other third-party payors	3.90%	3.80%
Patients	1.10%	1.80%
Total	100.00%	100.00%

Basis of Presentation Basis o35

Basis of Presentation Basis of Presentation - Textuals (Details)	9 Months Ended
	Sep. 30, 2015
Segment Reporting Information [Line Items]
Initial Suspension Period of Medicare Payments	180 days
Medicare Denials, Percentage Collected After Appeal	69.00%
Medicare Denials, Percentage Collected After Appeal, Including Administrative Law Judge Hearings	73.00%
RAC Audits [Member]
Segment Reporting Information [Line Items]
Percentage of average annual patient discharges requested for review, less than	1.00%

Business Combinations - Table 1

Business Combinations - Table 1 (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill	$ 1,105	$ 1,084
Inpatient Rehabilitation Hospital [Member]
Business Acquisition [Line Items]
Total current assets	10.1
Property and equipment, net	42.7
Goodwill	0.7
Total assets acquired	63.4
Total liabilities assumed	(2.7)
Net assets acquired	60.7
Inpatient Rehabilitation Hospital [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	0.1
Inpatient Rehabilitation Hospital [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	$ 0.8
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	20 years
Inpatient Rehabilitation Hospital [Member] | Certificate of Need [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	$ 8.8
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	20 years
Inpatient Rehabilitation Hospital [Member] | License [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	$ 0.2
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	20 years
Inpatient Rehabilitation Hospital [Member] | Minimum [Member] | Noncompete Agreements [Member]
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	2 years
Inpatient Rehabilitation Hospital [Member] | Maximum [Member] | Noncompete Agreements [Member]
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	3 years

Business Combinations - Table 2

Business Combinations - Table 2 (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Net Cash Paid For All Acquisitions During Each Period Presented
Net cash paid for acquisition				$ 87.1	$ 15.9
Inpatient Rehabilitation Hospital [Member]
Net Cash Paid For All Acquisitions During Each Period Presented
Fair value of assets acquired		$ 0	$ 0	62.8	52
Goodwill	$ 0.7	0	0	0.7	34.8
Fair value of liabilities assumed		0	0	(2.7)	(21.9)
Fair value of noncontrolling interests owned by joint venture partner		0	0	(4.2)	(14)
Fair value of equity interest prior to acquisition		0	0	0	(35)
Net cash paid for acquisition		$ 0	$ 0	$ 56.6	$ 15.9

Business Combinations Business

Business Combinations Business Combinations - Table 3 (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill	$ 1,105	$ 1,084
Home Health and Hospice [Member]
Business Acquisition [Line Items]
Property and equipment, net	0.1
Goodwill	20.3
Total assets acquired	30.7
Total liabilities assumed	(0.2)
Net assets acquired	30.5
Noncompete Agreements [Member] | Home Health and Hospice [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	1.3
Trade Names [Member] | Home Health and Hospice [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	$ 0.5
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	1 year
Certificate of Need [Member] | Home Health and Hospice [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	$ 4.9
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	10 years
License [Member] | Home Health and Hospice [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	$ 3.6
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	10 years
Minimum [Member] | Noncompete Agreements [Member] | Home Health and Hospice [Member]
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	2 years
Maximum [Member] | Noncompete Agreements [Member] | Home Health and Hospice [Member]
Useful Lives of Acquired Finite-Lived Intangible Assets [Abstract]
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	5 years

Business Combinations Busines39

Business Combinations Business Combinations - Table 4 (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Net cash paid for acquisition			$ 87.1	$ 15.9
Home Health and Hospice [Member]
Business Acquisition [Line Items]
Fair value of assets acquired	$ 1.9	$ 0	10.4	0
Goodwill	7.5	0	20.3	0
Fair value of liabilities assumed	(0.1)	0	(0.2)	0
Net cash paid for acquisition	$ 9.3	$ 0	$ 30.5	$ 0

Business Combinations - Table 5

Business Combinations - Table 5 (Details) - USD ($) $ in Millions	3 Months Ended		7 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Summary of Actual and Pro Forma Results of Operations for Acquisitions
Acquired entity only: Actual from acquisition date to September 30, 2015, Net Operating Revenues			$ 40.8
Acquired entities only: Actual from acquisition date to September 30, 2015, Net Income Attributable to HealthSouth			$ 0.6
Combined entity: Supplemental pro forma, Net Operating Revenues	$ 778.9	$ 621.5		$ 2,316.3	$ 1,863.9
Combined entity: Supplemental pro forma, Net Income Attributable to HealthSouth	$ 50.7	$ 51.2		$ 136.6	$ 181.3

Business Combinations - Textual

Business Combinations - Textual (Details) $ in Millions	1 Months Ended			3 Months Ended		9 Months Ended
	Oct. 31, 2015USD ($)	Aug. 31, 2015USD ($)	Apr. 30, 2015USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Oct. 01, 2015	May. 31, 2015
Business Acquisition (Textual) [Abstract]
Net cash paid for acquisition						$ 87.1	$ 15.9
Inpatient Rehabilitation Hospital [Member]
Business Acquisition (Textual) [Abstract]
Number of Beds Acquired			50						158
Net cash paid for acquisition				$ 0	$ 0	56.6	15.9
Noncontrolling Interest, Ownership Percentage by Parent			83.00%
Goodwill, Acquired During Period			$ 0.7	0	0	0.7	34.8
Number of Beds Acquired, Skilled Nursing Facility									74
Business Acquisition, Goodwill, Expected Tax Deductible Amount			$ 0
Home Health and Hospice [Member]
Business Acquisition (Textual) [Abstract]
Net cash paid for acquisition				9.3	0	30.5	0
Payments to Acquire Businesses, Gross		$ 170
Goodwill, Acquired During Period				7.5	$ 0	20.3	$ 0
Business Acquisition, Goodwill, Expected Tax Deductible Amount				$ 20.3		$ 20.3
Subsequent Event [Member] | Inpatient Rehabilitation Hospital [Member]
Business Acquisition (Textual) [Abstract]
Number of Locations of an Acquired Entity								11
Number of Beds Acquired								902
Net cash paid for acquisition	$ 730

Investments In and Advances t42

Investments In and Advances to Nonconsolidated Affiliates - Table 1 (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Equity Method Investment, Summarized Financial Information, Income Statement [Abstract]
Net operating revenues	$ 9.2	$ 7.8	$ 26.3	$ 44.1
Operating expenses	(4)	(3.3)	(11.7)	(22.7)
Income from continuing operations, net of tax	5.1	4.2	13.8	28.2
Net income	$ 5.1	$ 4.2	$ 13.8	$ 28.2

Investments in and Advances t43

Investments in and Advances to Nonconsolidated Affiliates - Textual (Details) $ in Millions	Sep. 30, 2015USD ($)facilities	Dec. 31, 2014USD ($)
Investments In and Advances to Nonconsolidated Affiliates (Textual) [Abstract]
Investments In and Advances To Nonconsolidated Affiliates | $	$ 11.1	$ 9.4
Number of Partially Owned Subsidiaries, Nonconsolidated	9
Number of General or Limited Partnerships, Limited Liability Companies, or Joint Ventures, Nonconsolidated	8
Minimum [Member]
Investments In and Advances to Nonconsolidated Affiliates (Textual) [Abstract]
Nonconsolidated Affiliates, Ownership Percentage	1.00%
Maximum [Member]
Investments In and Advances to Nonconsolidated Affiliates (Textual) [Abstract]
Nonconsolidated Affiliates, Ownership Percentage	51.00%

Long-term Debt - Table 1 (Detai

Long-term Debt - Table 1 (Details) - USD ($) $ in Millions	Sep. 30, 2015	Jul. 29, 2015	Dec. 31, 2014
Schedule of Outstanding Long-term Debt
Advances under revolving credit facility	$ 25		$ 325
Other notes payable	40.3		41.6
Capital lease obligations	82.1		86.7
Total debt and capital lease obligations	2,824.3		2,131.6
Less: Current portion	(23.6)		(20.8)
Long-term debt, net of current portion	2,800.7		2,110.8
Term Loan Facilities [Member]
Schedule of Outstanding Long-term Debt
Term loan facilities	320	$ 195	450
8.125% Senior Notes Due 2020 [Member]
Schedule of Outstanding Long-term Debt
Senior Notes	0		287
7.75% Senior Notes Due 2022 [Member]
Schedule of Outstanding Long-term Debt
Senior Notes	227		227.1
5.125% Senior Notes Due 2023 [Member]
Schedule of Outstanding Long-term Debt
Senior Notes	300		0
5.75% Senior Notes Due 2024 [Member]
Schedule of Outstanding Long-term Debt
Senior Notes	1,215.2		456.2
5.75% Senior Notes Due 2025 [Member]
Schedule of Outstanding Long-term Debt
Senior Notes	350		0
2.00% Convertible Senior Subordinated Notes due 2043 [Member]
Schedule of Outstanding Long-term Debt
Convertible Subordinated Debt	$ 264.7		$ 258

Long-term Debt - Table 2 (Detai

Long-term Debt - Table 2 (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Long-term Debt by Maturity
Total debt and capital lease obligations	$ 2,824.3	$ 2,131.6
Face Amount [Member]
Long-term Debt by Maturity
October 1 through December 31, 2015	3.4
2,016	27.3
2,017	25.6
2,018	25
2,019	27.8
2,020	603
Thereafter	2,151.4
Total debt and capital lease obligations	2,863.5
Net Amount [Member]
Long-term Debt by Maturity
October 1 through December 31, 2015	3.4
2,016	27.3
2,017	25.6
2,018	25
2,019	27.8
2,020	547.7
Thereafter	2,167.5
Total debt and capital lease obligations	$ 2,824.3

Long-term Debt Long-term Debt -

Long-term Debt Long-term Debt - Table 3 (Details) - 5.125% Senior Notes Due 2023 [Member]	Mar. 31, 2015
2018 [Member]
Debt Instrument [Line Items]
Senior Notes, Redemption Price, Expressed as Percentage of Principal	103.844%
2019 [Member]
Debt Instrument [Line Items]
Senior Notes, Redemption Price, Expressed as Percentage of Principal	102.563%
2020 [Member]
Debt Instrument [Line Items]
Senior Notes, Redemption Price, Expressed as Percentage of Principal	101.281%
2021 and thereafter [Member]
Debt Instrument [Line Items]
Senior Notes, Redemption Price, Expressed as Percentage of Principal	100.00%

Long-term Debt Long-term Debt47

Long-term Debt Long-term Debt - Table 4 (Details) - 5.75% Senior Notes Due 2025 [Member]	Sep. 30, 2015
2020 [Member]
Debt Instrument [Line Items]
Senior Notes, Redemption Price, Expressed as Percentage of Principal	102.875%
2021 [Member]
Debt Instrument [Line Items]
Senior Notes, Redemption Price, Expressed as Percentage of Principal	101.917%
2022 [Member]
Debt Instrument [Line Items]
Senior Notes, Redemption Price, Expressed as Percentage of Principal	100.958%
2023 and thereafter [Member]
Debt Instrument [Line Items]
Senior Notes, Redemption Price, Expressed as Percentage of Principal	100.00%

Long-term Debt - Textual (Detai

Long-term Debt - Textual (Details) $ in Millions	Oct. 28, 2015USD ($)	Apr. 10, 2015USD ($)	Jan. 31, 2015USD ($)	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Jul. 01, 2017	Jun. 30, 2017	Sep. 01, 2015USD ($)	Aug. 31, 2015USD ($)	Jul. 29, 2015USD ($)	Jul. 28, 2015	Jun. 24, 2015USD ($)	Jun. 23, 2015USD ($)
Long Term Debt (Textual) [ Abstract]
Loss on early extinguishment of debt					$ 0	$ 18.8	$ 1.2		$ 0	$ 20	$ 0
Repayments of Long-term Debt										546.3	$ 5.7
Capital expenditures, permitted																		$ 350	$ 200
Financial Covenants Leverage Ratio, Maximum																4.50	4.25
Subsequent Event [Member]
Long Term Debt (Textual) [ Abstract]
Financial Covenants Leverage Ratio, Maximum													4.50
Term Loan Facilities [Member]
Long Term Debt (Textual) [ Abstract]
Term loan facility, draw					125			$ 375		125
Term Loan Facility, Maximum Borrowing Capacity																$ 500
Term loan facilities					$ 320			450		$ 320						195
Term loan facility, Unused Borrowing Capacity, Amount														$ 250
Revolving Credit Facility [Member]
Long Term Debt (Textual) [ Abstract]
Revolver, Amounts Drawn								$ 325
Line of Credit Facility, Maximum Borrowing Capacity																$ 600
8.125% Senior Notes Due 2020 [Member]
Long Term Debt (Textual) [ Abstract]
Senior Note, redemption price		104.063%
Repayments of Long-term Debt		$ 302
Senior Notes, Principal Extinguished		$ 290
Debt Instrument, Interest Rate, Stated Percentage					8.125%					8.125%
7.75% Senior Notes Due 2022 [Member]
Long Term Debt (Textual) [ Abstract]
Debt Instrument, Interest Rate, Stated Percentage					7.75%					7.75%
7.75% Senior Notes Due 2022 [Member] | Subsequent Event [Member]
Long Term Debt (Textual) [ Abstract]
Senior Note, redemption price	103.875%
Senior Notes, Portion of Principal Extinguished	$ 50
5.125% Senior Notes Due 2023 [Member]
Long Term Debt (Textual) [ Abstract]
Debt issuance, face amount							$ 300
Senior Note, issue price							100.00%
Senior Notes, proceeds from public offering							$ 295
Debt Instrument, Interest Rate, Stated Percentage					5.125%					5.125%
5.75% Senior Notes Due 2024 [Member]
Long Term Debt (Textual) [ Abstract]
Debt issuance, face amount			$ 400												$ 350
Senior Note, issue price			102.00%												100.50%
Senior Notes Issuance, Proceeds Used For Debt Reduction			$ 250
Senior Notes, Proceeds From Private Offering															$ 351
Debt Instrument, Interest Rate, Stated Percentage					5.75%					5.75%
5.75% Senior Notes Due 2025 [Member]
Long Term Debt (Textual) [ Abstract]
Debt issuance, face amount					$ 350					$ 350
Senior Note, issue price					100.00%					100.00%
Senior Notes, Proceeds From Private Offering					$ 344					$ 344
Debt Instrument, Interest Rate, Stated Percentage					5.75%					5.75%
2.00% Convertible Senior Subordinated Notes due 2043 [Member]
Long Term Debt (Textual) [ Abstract]
Debt Instrument, Interest Rate, Stated Percentage					2.00%					2.00%
Scenario, Forecast [Member]
Long Term Debt (Textual) [ Abstract]
Loss on early extinguishment of debt				$ 2
Repayments of Long-term Debt	$ 52
Financial Covenants Leverage Ratio, Maximum												4.25
Scenario, Forecast [Member] | Term Loan Facilities [Member]
Long Term Debt (Textual) [ Abstract]
Term loan facility, capacity				$ 125

Redeemable Noncontrolling Int49

Redeemable Noncontrolling Interests - Table 1 (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Redeemable Noncontrolling Interest [Line Items]
Balance at beginning of period			$ 84.7
Net Income attributable to noncontrolling interest	$ 3.7	$ 1.8	10.1	$ 5.4
Distributions declared			(36.7)	(33.7)
Change in fair value			(14.9)
Balance at end of period	114.1		114.1
Altoona and Jonesboro [Member]
Redeemable Noncontrolling Interest [Line Items]
Balance at beginning of period				13.5
Net Income attributable to noncontrolling interest				5.4
Distributions declared			(5.6)	(6.7)
Change in fair value				0
Balance at end of period		$ 12.2		$ 12.2
Altoona, Jonesboro, and Encompass [Member]
Redeemable Noncontrolling Interest [Line Items]
Balance at beginning of period			84.7
Net Income attributable to noncontrolling interest			10.1
Balance at end of period	$ 114.1		114.1
Encompass [Member]
Redeemable Noncontrolling Interest [Line Items]
Change in fair value			$ 24.9

Redeemable Noncontrolling Int50

Redeemable Noncontrolling Interests - Table 2 (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Redeemable Noncontrolling Interest [Line Items]
Net income attributable to nonredeemable noncontrolling interest	$ 13.4	$ 12.9	$ 40.8	$ 38.9
Net income attributable to redeemable noncontrolling interest	3.7	1.8	10.1	5.4
Net income attributable to noncontrolling interests	$ 17.1	$ 14.7	$ 50.9	$ 44.3

Fair Value Measurements - Table

Fair Value Measurements - Table 1 (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Option to purchase SCA stock		$ 9.9
Redeemable Noncontrolling Interest, Fair Value	$ 114.1	84.7
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Redeemable Noncontrolling Interest, Fair Value	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Redeemable Noncontrolling Interest, Fair Value	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Redeemable Noncontrolling Interest, Fair Value	114.1	84.7
Other Current Assets [Member] | Restricted Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Marketable Securities, Fair Value	$ 16.6	$ 4.6
Fair Value Measurements, Valuation Techniques	M	M
Other Current Assets [Member] | Restricted Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Marketable Securities, Fair Value	$ 0	$ 0
Other Current Assets [Member] | Restricted Marketable Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Marketable Securities, Fair Value	16.6	4.6
Other Current Assets [Member] | Restricted Marketable Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Marketable Securities, Fair Value	0	0
Other Long-term Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Option to purchase SCA stock		9.9
Other Long-term Assets [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Option to purchase SCA stock		0
Other Long-term Assets [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Option to purchase SCA stock		0
Other Long-term Assets [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Option to purchase SCA stock		9.9
Other Long-term Assets [Member] | Restricted Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Marketable Securities, Fair Value	$ 39.4	$ 45.9
Fair Value Measurements, Valuation Techniques	M	M
Other Long-term Assets [Member] | Restricted Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Marketable Securities, Fair Value	$ 0	$ 0
Other Long-term Assets [Member] | Restricted Marketable Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Marketable Securities, Fair Value	39.4	45.9
Other Long-term Assets [Member] | Restricted Marketable Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Marketable Securities, Fair Value	$ 0	$ 0
Redeemable Noncontrolling Interest [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Fair Value Measurements, Valuation Techniques	I	I
Surgical Care Affiliates [Member] | Other Long-term Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Fair Value Measurements, Valuation Techniques		M

Fair Value Measurements - Tab52

Fair Value Measurements - Table 2 (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Advances under revolving credit facility	$ 25	$ 325
Other notes payable	40.3	41.6
Revolving Credit Facility [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Advances under revolving credit facility	25	325
Revolving Credit Facility [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Advances under revolving credit facility, Fair Value	25	325
Term Loan Facilities [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Term loan facilities	320	450
Term Loan Facilities [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Term loan facilities, Fair Value	320	450
8.125% Senior Notes Due 2020 [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	0	287
8.125% Senior Notes Due 2020 [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	0	287
8.125% Senior Notes Due 2020 [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes, Fair Value	0	302.5
7.75% Senior Notes due 2022 [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	227	227.1
7.75% Senior Notes due 2022 [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	227	227.1
7.75% Senior Notes due 2022 [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes, Fair Value	235.9	240.7
5.125% Senior Notes Due 2023 [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	300	0
5.125% Senior Notes Due 2023 [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	300	0
5.125% Senior Notes Due 2023 [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes, Fair Value	289.8	0
5.75% Senior Notes Due 2024 [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	1,215.2	456.2
5.75% Senior Notes Due 2024 [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	1,215.2	456.2
5.75% Senior Notes Due 2024 [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes, Fair Value	1,182	471.4
5.75% Senior Notes Due 2025 [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	350	0
5.75% Senior Notes Due 2025 [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes	350	0
5.75% Senior Notes Due 2025 [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Senior Notes, Fair Value	340.4	0
2.00% Convertible Senior Subordinated Notes due 2043 [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Convertible Subordinated Debt	264.7	258
2.00% Convertible Senior Subordinated Notes due 2043 [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Convertible Subordinated Debt	264.7	258
2.00% Convertible Senior Subordinated Notes due 2043 [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Convertible Debt, Fair Value	362.4	358.4
Other Notes Payable [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Other notes payable	40.3	41.6
Other Notes Payable [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Other Notes Payable, Fair Value	40.3	41.6
Letters of Credit [Member] | Carrying Amount [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Letters of Credit	0	0
Letters of Credit [Member] | Estimated Fair Value [Member]
Carrying Amounts and Estimated Fair Values, Financial Instruments [Abstract]
Letters of Credit, Fair Value	$ 34.2	$ 31.8

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value Measurements - Textuals (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Apr. 13, 2015	Apr. 01, 2015	Dec. 31, 2014	Dec. 31, 2007
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Option Contract, Annual Premium								15.00%
Option Contract, Exercisable						30.00%		30.00%
Option to purchase SCA stock							$ 9.9
Derivative, Loss		$ (1.6)	$ (0.4)
Derivative, Gain on Derivative			2	$ 5.1
Available-for-sale Equity Securities, Gross Realized Gain	$ 0.6		1.2
Gain on consolidation of Fairlawn Rehabilitation Hospital			0	27.2
Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Option, Changes in Fair Value, Gain (Loss)	0		0
Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Option Contract, Equity Opportunity								5.00%
Surgical Care Affiliates [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Option Contract, Shares Received					326,242
Share Price					$ 35.43
Fairlawn Rehabilitation Hospital [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain on consolidation of Fairlawn Rehabilitation Hospital	$ 0	$ 0	$ 0	$ 27.2

Share-Based Payments - Textual

Share-Based Payments - Textual (Details) - shares shares in Millions	1 Months Ended	9 Months Ended
	Feb. 28, 2015	Sep. 30, 2015
Restricted Stock [Member]
Share-based Compensation (Textual) [Abstract]
Restricted Stock Awards Issued, Service Requirement Only	0.2
Restricted Stock [Member] | February 2015 and May 2015 [Member]
Share-based Compensation (Textual) [Abstract]
Restricted Stock Awards Issued		0.5
Stock Options [Member]
Share-based Compensation (Textual) [Abstract]
Stock Options Granted	0.1

Income Taxes - Table (Details)

Income Taxes - Table (Details) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Gross Unrecognized Income Tax Benefits [Abstract]
Unrecognized Tax Benefits, Beginning Balance	$ 0.9
Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions	1.5
Unrecognized Tax Benefits, Ending Balance	$ 2.4

Income Taxes - Textual (Details

Income Taxes - Textual (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Income Tax Contingency [Line Items]
Provision for income tax expense	$ 35.9	$ 22.1	$ 98.4	$ 91.4
Net Deferred Tax Assets, Total	241.3		241.3
Deferred Tax Assets, Valuation Allowance	22.9		22.9
Gross Operating Loss Carryforwards	393		393
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense			(14.5)
Gross Unrecognized Tax Benefits	2.4		2.4		$ 0.9
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	2.4		2.4		$ 0.9
Federal
Income Tax Contingency [Line Items]
Deferred Tax Assets, Net Operating Loss Carryforwards	$ 137.4		$ 137.4

Contingencies and Other Commi57

Contingencies and Other Commitments (Details)	12 Months Ended
	Dec. 31, 2004USD ($)	Dec. 31, 1995	Sep. 30, 2015	Feb. 28, 2015	Apr. 24, 2014	Mar. 04, 2013
Litigation, General Medicine [Member]
Contingencies (Textual) [Abstract]
Long-term Purchase Commitment, Time Period		3 years
Consent Judgment Awarded to Plaintiff	$ 376,000,000
Loss Contingency, Litigation Settlement, Consideration	$ 300,000
HHS-OIG Investigation [Member]
Contingencies (Textual) [Abstract]
Number of hospitals that received subpoenas					7	4
Number of patient medical records requested for each hospital in subpoenas						100
Number of hospitals that received supplemental subpoenas					2
Number of additional patient medical records requested				70
Compliance Threshold Under Health Care Act			60.00%

Segment Reporting Segment Rep58

Segment Reporting Segment Reporting - Table 1 (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Net operating revenues	$ 778.6	$ 596.9	$ 2,283.6	$ 1,792.5
Provision for Doubtful Accounts	(10.7)	(8.2)	(33.2)	(25)
Net operating revenues less provision for doubtful accounts	767.9	588.7	2,250.4	1,767.5
Costs and Expenses [Abstract]
Salaries and benefits	417.1	290	1,204	861.4
Other operating expenses	106.7	89.4	314.1	260.2
Supplies	31	26.6	94.1	82
Occupancy costs	12.5	10.3	37.1	31.1
Total segment level operating expenses	632	475.2	1,855.6	1,410.1
Other income	(0.7)	(0.2)	(4.2)	(30.1)
Equity in net income of nonconsolidated affiliates	(2.4)	(1.9)	(6.3)	(8.8)
Noncontrolling interest	(17.1)	(14.7)	(50.9)	(44.3)
Inpatient Rehabilitation Hospital [Member]
Segment Reporting Information [Line Items]
Net operating revenues	651.6	589.9	1,927.2	1,771.5
Provision for Doubtful Accounts	(10.2)	(8.1)	(31.4)	(24.7)
Net operating revenues less provision for doubtful accounts	641.4	581.8	1,895.8	1,746.8
Costs and Expenses [Abstract]
Salaries and benefits	326.8	285	950.8	846.1
Other operating expenses	95.8	86.1	284.5	252.8
Supplies	28.9	26.5	88.6	81.7
Occupancy costs	10.6	10.2	31.7	30.8
Total segment level operating expenses	462.1	407.8	1,355.6	1,211.4
Other income	(0.1)	(0.2)	(1)	(2.9)
Equity in net income of nonconsolidated affiliates	(2.4)	(1.9)	(6.3)	(8.8)
Noncontrolling interest	15.6	14.6	46.4	44
Segment Adjusted EBITDA	166.2	161.5	501.1	503.1
Capital Expenditures	43.8	46.1	103.2	146.6
Home Health and Hospice [Member]
Segment Reporting Information [Line Items]
Net operating revenues	127	7	356.4	21
Provision for Doubtful Accounts	(0.5)	(0.1)	(1.8)	(0.3)
Net operating revenues less provision for doubtful accounts	126.5	6.9	354.6	20.7
Costs and Expenses [Abstract]
Cost of services sold (excluding depreciation and amortization)	61.7	4.1	171.8	12.5
Support and overhead costs	42.6	1.7	121.7	5.1
Total segment level operating expenses	104.3	5.8	293.5	17.6
Other income	0	0	0	0
Equity in net income of nonconsolidated affiliates	0	0	0	0
Noncontrolling interest	1.5	0.1	4.5	0.3
Segment Adjusted EBITDA	20.7	1	56.6	2.8
Capital Expenditures	$ 0.5	$ 0	$ 2.7	$ 0

Segment Reporting Segment Rep59

Segment Reporting Segment Reporting - Table 2 (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 4,249.3	$ 3,408.8
Investments in and advances to nonconsolidated affiliates	11.1	9.4
Inpatient Rehabilitation Hospital [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	3,419.4	2,596.8
Investments in and advances to nonconsolidated affiliates	11.1	9.4
Home Health and Hospice [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	894.2	876.3
Investments in and advances to nonconsolidated affiliates	$ 0	$ 0

Segment Reporting Segment Rep60

Segment Reporting Segment Reporting - Table 3 (Details) - USD ($) $ in Millions	3 Months Ended				9 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
General and administrative expenses	$ (30.6)			$ (27.5)	$ (97.3)	$ (88.4)
Depreciation and amortization	(33.7)			(27.4)	(98.3)	(80.2)
Loss on disposal or impairment of assets	(0.9)			(2.7)	(0.2)	(5.7)
Government, class action, and related settlements	0			0	(8)	0.8
Professional fees - accounting, tax, and legal	(0.4)			(4)	(2.7)	(7.6)
Loss on early extinguishment of debt	0	$ (18.8)	$ (1.2)	0	(20)	0
Interest expense and amortization of debt discounts and fees	(35.6)			(27.8)	(98.3)	(83.5)
Gain on consolidation of former equity method hospital					0	27.2
Net income attributable to noncontrolling interests	17.1			14.7	50.9	44.3
Gain related to SCA equity interest	0.6			0	3.2	0
Income from continuing operations before income tax expense	103.4			87.8	287	312.8
Inpatient Rehabilitation Hospital and Home Health and Hospice [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total segment Adjusted EBITDA	186.9			162.5	557.7	505.9
Fairlawn Rehabilitation Hospital [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Gain on consolidation of former equity method hospital	$ 0			$ 0	$ 0	$ 27.2

Segment Reporting Segment Rep61

Segment Reporting Segment Reporting - Table 4 (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets for reportable segments	$ 4,249.3	$ 3,408.8
Reclassification of noncurrent deferred income tax liabilities to net noncurrent deferred income tax assets	(64.3)	(64.3)
Total assets	4,249.3	3,408.8
Inpatient Rehabilitation Hospital and Home Health and Hospice [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets for reportable segments	4,313.6	3,473.1
Total assets	$ 4,313.6	$ 3,473.1

Segment Reporting Segment Rep62

Segment Reporting Segment Reporting - Table 5 (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	$ 778.6	$ 596.9	$ 2,283.6	$ 1,792.5
Inpatient Rehabilitation Hospital [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	651.6	589.9	1,927.2	1,771.5
Inpatient [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	625.1	563.7	1,850.4	1,691.6
Outpatient and other [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	26.5	26.2	76.8	79.9
Home Health and Hospice [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	127	7	356.4	21
Home health [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	118.3	7	333.7	21
Hospice [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	$ 8.7	$ 0	$ 22.7	$ 0

Segment Reporting Segment Rep63

Segment Reporting Segment Reporting - Textuals (Details)	Sep. 30, 2015facilities	Dec. 31, 2014
Segment Reporting Information [Line Items]
Number of Home Health Locations Before Encompass Acquisition		25
Inpatient Rehabilitation Hospital [Member]
Segment Reporting Information [Line Items]
Number of States in which Entity Operates	29
Number of Inpatient Rehabilitation Hospitals	109
Number of Joint Venture Hospitals Accounted for Using the Equity Method	1
Number of Inpatient Rehabilitation Units Under Management Contracts	3
Home Health and Hospice [Member]
Segment Reporting Information [Line Items]
Number of States in which Entity Operates	18
Number of Hospital Based Home Health and Hospice Agencies	164

Condensed Consolidating Finan64

Condensed Consolidating Financial Information - Income Statement Tables (Details) - USD ($) $ in Millions	3 Months Ended				9 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Condensed Consolidating Statements of Operations
Net operating revenues	$ 778.6			$ 596.9	$ 2,283.6	$ 1,792.5
Less: Provision for doubtful accounts	(10.7)			(8.2)	(33.2)	(25)
Net operating revenues less provision for doubtful accounts	767.9			588.7	2,250.4	1,767.5
Operating expenses:
Salaries and benefits	417.1			290	1,204	861.4
Other operating expenses	106.7			89.4	314.1	260.2
Occupancy costs	12.5			10.3	37.1	31.1
Supplies	31			26.6	94.1	82
General and administrative expenses	30.6			27.5	97.3	88.4
Depreciation and amortization	33.7			27.4	98.3	80.2
Government, class action, and related settlements	0			0	8	(0.8)
Professional fees - accounting, tax, and legal	0.4			4	2.7	7.6
Total operating expenses	632			475.2	1,855.6	1,410.1
Loss on early extinguishment of debt	0	$ 18.8	$ 1.2	0	20	0
Interest expense and amortization of debt discounts and fees	35.6			27.8	98.3	83.5
Other income	(0.7)			(0.2)	(4.2)	(30.1)
Equity in net income of nonconsolidated affiliates	(2.4)			(1.9)	(6.3)	(8.8)
Equity in net income of consolidated affiliates	0			0	0	0
Management fees	0			0	0	0
Income from continuing operations before income tax expense	103.4			87.8	287	312.8
Provision for income tax (benefit) expense	35.9			22.1	98.4	91.4
Income from continuing operations	67.5			65.7	188.6	221.4
Income (loss) from discontinued operations, net of tax	0.3			(0.9)	(1.6)	2.8
Net income	67.8			64.8	187	224.2
Less: Net income attributable to noncontrolling interests	(17.1)			(14.7)	(50.9)	(44.3)
Net income attributable to HealthSouth	50.7			50.1	136.1	179.9
Comprehensive income	67			64.7	186.4	224.2
Comprehensive income attributable to HealthSouth	49.9			50	135.5	179.9
HealthSouth Corporation [Member]
Condensed Consolidating Statements of Operations
Net operating revenues	4.3			4	14.7	11.5
Less: Provision for doubtful accounts	0			0	0	0
Net operating revenues less provision for doubtful accounts	4.3			4	14.7	11.5
Operating expenses:
Salaries and benefits	14.7			4.1	35	15.9
Other operating expenses	6.5			5	22.7	15
Occupancy costs	1.1			1.1	3.2	3.1
Supplies	0			0.1	0	0
General and administrative expenses	27.8			27.5	93.6	88.4
Depreciation and amortization	2.6			2.3	7.3	7.4
Government, class action, and related settlements					8	(0.8)
Professional fees - accounting, tax, and legal	0.4			4	2.7	7.6
Total operating expenses	53.1			44.1	172.5	136.6
Loss on early extinguishment of debt					20
Interest expense and amortization of debt discounts and fees	33.4			25.7	91	76.3
Other income	(2.5)			0.1	(9.6)	(0.3)
Equity in net income of nonconsolidated affiliates	0			0	0	0
Equity in net income of consolidated affiliates	(80.4)			(62.6)	(241)	(233.9)
Management fees	(29.2)			(26.8)	(87)	(80.7)
Income from continuing operations before income tax expense	29.9			23.5	68.8	113.5
Provision for income tax (benefit) expense	(20.5)			(27.5)	(68.9)	(63.5)
Income from continuing operations	50.4			51	137.7	177
Income (loss) from discontinued operations, net of tax	0.3			(0.9)	(1.6)	2.9
Net income	50.7			50.1	136.1	179.9
Less: Net income attributable to noncontrolling interests	0			0	0	0
Net income attributable to HealthSouth	50.7			50.1	136.1	179.9
Comprehensive income	49.9			50	135.5	179.9
Comprehensive income attributable to HealthSouth	49.9			50	135.5	179.9
Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Operations
Net operating revenues	468.6			424.5	1,394.8	1,286.4
Less: Provision for doubtful accounts	(7.7)			(5.7)	(25)	(17.6)
Net operating revenues less provision for doubtful accounts	460.9			418.8	1,369.8	1,268.8
Operating expenses:
Salaries and benefits	218.9			197.9	647	590.2
Other operating expenses	68.2			62	199.6	182.1
Occupancy costs	16.9			14.5	48.6	43.4
Supplies	20.2			18.6	62.2	57.9
General and administrative expenses	0			0	0	0
Depreciation and amortization	20			18.2	58.7	54.1
Government, class action, and related settlements					0	0
Professional fees - accounting, tax, and legal	0			0	0	0
Total operating expenses	344.2			311.2	1,016.1	927.7
Loss on early extinguishment of debt					0
Interest expense and amortization of debt discounts and fees	2.1			1.7	6.6	5.9
Other income	(0.1)			0	(0.2)	(28.4)
Equity in net income of nonconsolidated affiliates	(2.4)			(1.9)	(6.3)	(8.8)
Equity in net income of consolidated affiliates	(9.2)			(7.2)	(25.4)	(21.3)
Management fees	22.2			20.4	66.2	61.6
Income from continuing operations before income tax expense	104.1			94.6	312.8	332.1
Provision for income tax (benefit) expense	39.5			39.2	118.9	122
Income from continuing operations	64.6			55.4	193.9	210.1
Income (loss) from discontinued operations, net of tax	0			0	0	0
Net income	64.6			55.4	193.9	210.1
Less: Net income attributable to noncontrolling interests	0			0	0	0
Net income attributable to HealthSouth	64.6			55.4	193.9	210.1
Comprehensive income	64.6			55.4	193.9	210.1
Comprehensive income attributable to HealthSouth	64.6			55.4	193.9	210.1
Nonguarantor Subsidiaries [Member]
Condensed Consolidating Statements of Operations
Net operating revenues	331.7			191.2	950.5	561.7
Less: Provision for doubtful accounts	(3)			(2.5)	(8.2)	(7.4)
Net operating revenues less provision for doubtful accounts	328.7			188.7	942.3	554.3
Operating expenses:
Salaries and benefits	187.7			91.8	534.5	266.6
Other operating expenses	42			31.8	122.4	90
Occupancy costs	6.3			4.3	18.6	13.5
Supplies	10.8			7.9	31.9	24.1
General and administrative expenses	2.8			0	3.7	0
Depreciation and amortization	11.1			6.9	32.3	18.7
Government, class action, and related settlements					0	0
Professional fees - accounting, tax, and legal	0			0	0	0
Total operating expenses	260.7			142.7	743.4	412.9
Loss on early extinguishment of debt					0
Interest expense and amortization of debt discounts and fees	2.7			0.7	8.2	2.1
Other income	(0.7)			(0.6)	(1.9)	(2.2)
Equity in net income of nonconsolidated affiliates	0			0	0	0
Equity in net income of consolidated affiliates	0			0	0	0
Management fees	7			6.4	20.8	19.1
Income from continuing operations before income tax expense	59			39.5	171.8	122.4
Provision for income tax (benefit) expense	16.9			10.4	48.4	32.9
Income from continuing operations	42.1			29.1	123.4	89.5
Income (loss) from discontinued operations, net of tax	0			0	0	(0.1)
Net income	42.1			29.1	123.4	89.4
Less: Net income attributable to noncontrolling interests	(17.1)			(14.7)	(50.9)	(44.3)
Net income attributable to HealthSouth	25			14.4	72.5	45.1
Comprehensive income	42.1			29.1	123.4	89.4
Comprehensive income attributable to HealthSouth	25			14.4	72.5	45.1
Eliminating Entries [Member]
Condensed Consolidating Statements of Operations
Net operating revenues	(26)			(22.8)	(76.4)	(67.1)
Less: Provision for doubtful accounts	0			0	0	0
Net operating revenues less provision for doubtful accounts	(26)			(22.8)	(76.4)	(67.1)
Operating expenses:
Salaries and benefits	(4.2)			(3.8)	(12.5)	(11.3)
Other operating expenses	(10)			(9.4)	(30.6)	(26.9)
Occupancy costs	(11.8)			(9.6)	(33.3)	(28.9)
Supplies	0			0	0	0
General and administrative expenses	0			0	0	0
Depreciation and amortization	0			0	0	0
Government, class action, and related settlements					0	0
Professional fees - accounting, tax, and legal	0			0	0	0
Total operating expenses	(26)			(22.8)	(76.4)	(67.1)
Loss on early extinguishment of debt					0
Interest expense and amortization of debt discounts and fees	(2.6)			(0.3)	(7.5)	(0.8)
Other income	2.6			0.3	7.5	0.8
Equity in net income of nonconsolidated affiliates	0			0	0	0
Equity in net income of consolidated affiliates	89.6			69.8	266.4	255.2
Management fees	0			0	0	0
Income from continuing operations before income tax expense	(89.6)			(69.8)	(266.4)	(255.2)
Provision for income tax (benefit) expense	0			0	0	0
Income from continuing operations	(89.6)			(69.8)	(266.4)	(255.2)
Income (loss) from discontinued operations, net of tax	0			0	0	0
Net income	(89.6)			(69.8)	(266.4)	(255.2)
Less: Net income attributable to noncontrolling interests	0			0	0	0
Net income attributable to HealthSouth	(89.6)			(69.8)	(266.4)	(255.2)
Comprehensive income	(89.6)			(69.8)	(266.4)	(255.2)
Comprehensive income attributable to HealthSouth	$ (89.6)			$ (69.8)	$ (266.4)	$ (255.2)

Condensed Consolidating Finan65

Condensed Consolidating Financial Information - Balance Sheet Tables (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 801.6	$ 66.7	$ 272.3	$ 64.5
Accounts receivable, net	350.9	323.2
Deferred income tax assets	185.9	188.4
Other current assets	124.6	108.3
Total current assets	1,463	686.6
Property and equipment, net	1,079.1	1,019.7
Goodwill	1,105	1,084
Intangible assets, net	324.7	306.1
Deferred income tax assets	55.4	129.4
Other long-term assets	222.1	183
Intercompany receivable and investments in consolidated affiliates	0	0
Total assets	4,249.3	3,408.8
Current liabilities:
Current portion of long-term debt	23.6	20.8
Accounts payable	65.6	53.4
Accrued expenses and other current liabilities	314.4	290.1
Total current liabilities	403.6	364.3
Long-term debt, net of current portion	2,800.7	2,110.8
Other long-term liabilities	140.7	136.3
Intercompany payable	0	0
Total Liabilities	$ 3,345	$ 2,611.4
Commitments and contingencies
Convertible perpetual preferred stock	$ 0	$ 93.2
Redeemable noncontrolling interests	114.1	84.7
Shareholders' equity:
HealthSouth shareholders’ equity	630.4	473.2
Noncontrolling interests	159.8	146.3
Total shareholders' equity	790.2	619.5	592.8	468.7
Total liabilities and shareholders' equity	4,249.3	3,408.8
HealthSouth Corporation [Member]
Current assets:
Cash and cash equivalents	786.7	41.9	266.5	60.5
Accounts receivable, net	0	0
Deferred income tax assets	122.7	125
Other current assets	43	30.9
Total current assets	952.4	197.8
Property and equipment, net	14.9	16.1
Goodwill	0	0
Intangible assets, net	11.9	11.3
Deferred income tax assets	89.4	163.3
Other long-term assets	474	461.3
Intercompany receivable and investments in consolidated affiliates	1,983.6	1,898.7
Total assets	3,526.2	2,748.5
Current liabilities:
Current portion of long-term debt	29.8	27.9
Accounts payable	9.8	9.3
Accrued expenses and other current liabilities	125.5	107.1
Total current liabilities	165.1	144.3
Long-term debt, net of current portion	2,690	1,993.7
Other long-term liabilities	40.7	44.1
Intercompany payable	0	0
Total Liabilities	$ 2,895.8	$ 2,182.1
Commitments and contingencies
Convertible perpetual preferred stock		$ 93.2
Redeemable noncontrolling interests	$ 0	0
Shareholders' equity:
HealthSouth shareholders’ equity	630.4	473.2
Noncontrolling interests	0	0
Total shareholders' equity	630.4	473.2
Total liabilities and shareholders' equity	3,526.2	2,748.5
Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	0.1	1.5	1.5	2.3
Accounts receivable, net	227.2	202.6
Deferred income tax assets	39.8	39.8
Other current assets	17.7	15.1
Total current assets	284.8	259
Property and equipment, net	779.4	752
Goodwill	278.1	279.6
Intangible assets, net	60.9	50.6
Deferred income tax assets	17.5	17.5
Other long-term assets	66.6	42.5
Intercompany receivable and investments in consolidated affiliates	0	0
Total assets	1,487.3	1,401.2
Current liabilities:
Current portion of long-term debt	4.4	4.2
Accounts payable	32.8	29.5
Accrued expenses and other current liabilities	75.3	72.6
Total current liabilities	112.5	106.3
Long-term debt, net of current portion	81	83.9
Other long-term liabilities	12	12.7
Intercompany payable	240.8	368.7
Total Liabilities	$ 446.3	$ 571.6
Commitments and contingencies
Convertible perpetual preferred stock		$ 0
Redeemable noncontrolling interests	$ 0	0
Shareholders' equity:
HealthSouth shareholders’ equity	1,041	829.6
Noncontrolling interests	0	0
Total shareholders' equity	1,041	829.6
Total liabilities and shareholders' equity	1,487.3	1,401.2
Nonguarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	14.8	23.3	4.3	1.7
Accounts receivable, net	123.7	120.6
Deferred income tax assets	23.4	23.6
Other current assets	100.5	81.1
Total current assets	262.4	248.6
Property and equipment, net	284.8	251.6
Goodwill	826.9	804.4
Intangible assets, net	251.9	244.2
Deferred income tax assets	0	0
Other long-term assets	67.5	64.3
Intercompany receivable and investments in consolidated affiliates	0	0
Total assets	1,693.5	1,613.1
Current liabilities:
Current portion of long-term debt	6.9	6.2
Accounts payable	23	14.6
Accrued expenses and other current liabilities	132.7	111.7
Total current liabilities	162.6	132.5
Long-term debt, net of current portion	415.7	418.3
Other long-term liabilities	139.1	130.9
Intercompany payable	182.7	195.5
Total Liabilities	$ 900.1	$ 877.2
Commitments and contingencies
Convertible perpetual preferred stock		$ 0
Redeemable noncontrolling interests	$ 114.1	84.7
Shareholders' equity:
HealthSouth shareholders’ equity	519.5	504.9
Noncontrolling interests	159.8	146.3
Total shareholders' equity	679.3	651.2
Total liabilities and shareholders' equity	1,693.5	1,613.1
Eliminating Entries [Member]
Current assets:
Cash and cash equivalents	0	0	$ 0	$ 0
Accounts receivable, net	0	0
Deferred income tax assets	0	0
Other current assets	(36.6)	(18.8)
Total current assets	(36.6)	(18.8)
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Deferred income tax assets	(51.5)	(51.4)
Other long-term assets	(386)	(385.1)
Intercompany receivable and investments in consolidated affiliates	(1,983.6)	(1,898.7)
Total assets	(2,457.7)	(2,354)
Current liabilities:
Current portion of long-term debt	(17.5)	(17.5)
Accounts payable	0	0
Accrued expenses and other current liabilities	(19.1)	(1.3)
Total current liabilities	(36.6)	(18.8)
Long-term debt, net of current portion	(386)	(385.1)
Other long-term liabilities	(51.1)	(51.4)
Intercompany payable	(423.5)	(564.2)
Total Liabilities	$ (897.2)	$ (1,019.5)
Commitments and contingencies
Convertible perpetual preferred stock		$ 0
Redeemable noncontrolling interests	$ 0	0
Shareholders' equity:
HealthSouth shareholders’ equity	(1,560.5)	(1,334.5)
Noncontrolling interests	0	0
Total shareholders' equity	(1,560.5)	(1,334.5)
Total liabilities and shareholders' equity	$ (2,457.7)	$ (2,354)

Condensed Consolidating Finan66

Condensed Consolidating Financial Information - Cash Flow Statement Tables (Details) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities	$ 368.2	$ 374.7
Cash flows from investing activities:
Purchases of property and equipment	(85.2)	(133.9)
Capitalized software costs	(20.7)	(12.6)
Acquisition of business, net of cash acquired	(87.1)	(15.9)
Proceeds from sale of marketable securities	12.8	2.7
Purchase of Restricted Investments	(6.5)	(2.5)
Other	7.3	(0.1)
Net cash used in investing activities	(179.4)	(162.3)
Cash flows from financing activities:
Principal borrowings under term loan facilities	125	0
Proceeds from bond issuance	1,400	175
Principal payments on debt, including pre-payments	(546.3)	(5.7)
Borrowings on revolving credit facility	315	65
Payments on revolving credit facility	(615)	(110)
Debt amendment and issuance costs	(31.3)	(3.1)
Repurchase of common stock, including fees and expenses	0	(43.1)
Dividends paid on common stock	(56.3)	(47.4)
Dividends paid on convertible perpetual preferred stock	(3.1)	(4.7)
Distributions paid to noncontrolling interests of consolidated affiliates	(39.7)	(39.6)
Other	(2.2)	9
Change in intercompany advances	0	0
Net cash provided by (used in) financing activities	546.1	(4.6)
Increase (decrease) in cash and cash equivalents	734.9	207.8
Cash and cash equivalents at beginning of period	66.7	64.5
Cash and cash equivalents at end of period	$ 801.6	272.3
Condensed Consolidating Financial Information (Textual) [Abstract]
HealthSouth ownership percentage of subsidiary guarantors	100.00%
Senior secured leverage ratio maximum	1.75
Consolidated coverage ratio minimum	2
HealthSouth Corporation [Member]
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities	$ 13.9	53.5
Cash flows from investing activities:
Purchases of property and equipment	(10)	(11.9)
Capitalized software costs	(19)	(4.1)
Acquisition of business, net of cash acquired	(56.6)	0
Proceeds from sale of marketable securities	12.8	0
Purchase of Restricted Investments	0	0
Other	13.6	1
Net cash used in investing activities	(59.2)	(15)
Cash flows from financing activities:
Principal borrowings under term loan facilities	125
Proceeds from bond issuance	1,400	175
Principal payments on debt, including pre-payments	(545)	(1.5)
Borrowings on revolving credit facility	315	65
Payments on revolving credit facility	(615)	(110)
Debt amendment and issuance costs	(31.3)	(3.1)
Repurchase of common stock, including fees and expenses		(43.1)
Dividends paid on common stock	(56.3)	(47.4)
Dividends paid on convertible perpetual preferred stock	(3.1)	(4.7)
Distributions paid to noncontrolling interests of consolidated affiliates	0	0
Other	1.8	13.3
Change in intercompany advances	199	124
Net cash provided by (used in) financing activities	790.1	167.5
Increase (decrease) in cash and cash equivalents	744.8	206
Cash and cash equivalents at beginning of period	41.9	60.5
Cash and cash equivalents at end of period	786.7	266.5
Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities	189.9	206.9
Cash flows from investing activities:
Purchases of property and equipment	(31.5)	(97.9)
Capitalized software costs	(0.4)	(1.5)
Acquisition of business, net of cash acquired	0	0
Proceeds from sale of marketable securities	0	0
Purchase of Restricted Investments	0	0
Other	3.3	1.3
Net cash used in investing activities	(28.6)	(98.1)
Cash flows from financing activities:
Principal borrowings under term loan facilities	0
Proceeds from bond issuance	0	0
Principal payments on debt, including pre-payments	(0.8)	(1.1)
Borrowings on revolving credit facility	0	0
Payments on revolving credit facility	0	0
Debt amendment and issuance costs	0	0
Repurchase of common stock, including fees and expenses		0
Dividends paid on common stock	0	0
Dividends paid on convertible perpetual preferred stock	0	0
Distributions paid to noncontrolling interests of consolidated affiliates	0	0
Other	(0.5)	(1.9)
Change in intercompany advances	(161.4)	(106.6)
Net cash provided by (used in) financing activities	(162.7)	(109.6)
Increase (decrease) in cash and cash equivalents	(1.4)	(0.8)
Cash and cash equivalents at beginning of period	1.5	2.3
Cash and cash equivalents at end of period	0.1	1.5
Nonguarantor Subsidiaries [Member]
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities	164	114.3
Cash flows from investing activities:
Purchases of property and equipment	(43.7)	(24.1)
Capitalized software costs	(1.3)	(7)
Acquisition of business, net of cash acquired	(30.5)	(15.9)
Proceeds from sale of marketable securities	0	2.7
Purchase of Restricted Investments	(6.5)	(2.5)
Other	3.4	(2.4)
Net cash used in investing activities	(78.6)	(49.2)
Cash flows from financing activities:
Principal borrowings under term loan facilities	0
Proceeds from bond issuance	0	0
Principal payments on debt, including pre-payments	(15.5)	(3.1)
Borrowings on revolving credit facility	0	0
Payments on revolving credit facility	0	0
Debt amendment and issuance costs	0	0
Repurchase of common stock, including fees and expenses		0
Dividends paid on common stock	0	0
Dividends paid on convertible perpetual preferred stock	0	0
Distributions paid to noncontrolling interests of consolidated affiliates	(39.7)	(39.6)
Other	(1.5)	(2.4)
Change in intercompany advances	(37.2)	(17.4)
Net cash provided by (used in) financing activities	(93.9)	(62.5)
Increase (decrease) in cash and cash equivalents	(8.5)	2.6
Cash and cash equivalents at beginning of period	23.3	1.7
Cash and cash equivalents at end of period	14.8	4.3
Eliminating Entries [Member]
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities	0.4	0
Cash flows from investing activities:
Purchases of property and equipment	0	0
Capitalized software costs	0	0
Acquisition of business, net of cash acquired	0	0
Proceeds from sale of marketable securities	0	0
Purchase of Restricted Investments	0	0
Other	(13)	0
Net cash used in investing activities	(13)	0
Cash flows from financing activities:
Principal borrowings under term loan facilities	0
Proceeds from bond issuance	0	0
Principal payments on debt, including pre-payments	15	0
Borrowings on revolving credit facility	0	0
Payments on revolving credit facility	0	0
Debt amendment and issuance costs	0	0
Repurchase of common stock, including fees and expenses		0
Dividends paid on common stock	0	0
Dividends paid on convertible perpetual preferred stock	0	0
Distributions paid to noncontrolling interests of consolidated affiliates	0	0
Other	(2)	0
Change in intercompany advances	(0.4)	0
Net cash provided by (used in) financing activities	12.6	0
Increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	$ 0	$ 0

Condensed Consolidating Finan67

Condensed Consolidating Financial Information Condensed Consolidating Financial Information - Textuals (Details) $ in Millions	Dec. 31, 2014USD ($)
Nonguarantor Subsidiaries [Member] | Scenario, Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Deferred Tax Assets, Noncurrent	$ 51.4

Earnings per Common Share - Tab

Earnings per Common Share - Table 1 (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Numerator:
Income from continuing operations	$ 67.5	$ 65.7	$ 188.6	$ 221.4
Less: Net income attributable to noncontrolling interests included in continuing operations	(17.1)	(14.7)	(50.9)	(44.3)
Less: Income allocated to participating securities	(0.3)	(0.5)	(0.9)	(2.1)
Less: Convertible perpetual preferred stock dividends	0	(1.6)	(1.6)	(4.7)
Income from continuing operations attributable to HealthSouth common shareholders	50.1	48.9	135.2	170.3
Income (loss) from discontinued operations, net of tax	0.3	(0.9)	(1.6)	2.8
Net income attributable to HealthSouth common shareholders	$ 50.4	$ 48	$ 133.6	$ 173.1
Denominator:
Basic weighted average common shares outstanding	90.6	86.5	89.1	86.8
Basic earnings per share attributable to HealthSouth common shareholders:
Continuing operations	$ 0.56	$ 0.56	$ 1.52	$ 1.96
Discontinued operations	0	(0.01)	(0.02)	0.03
Net Income	$ 0.56	$ 0.55	$ 1.50	$ 1.99
Numerator
Income from continuing operations	$ 67.5	$ 65.7	$ 188.6	$ 221.4
Less: Net income attributable to noncontrolling interests included in continuing operations	(17.1)	(14.7)	(50.9)	(44.3)
Add: Interest on convertible debt, net of tax	2.4	2.3	7	6.8
Income from continuing operations attributable to HealthSouth common shareholders	52.8	53.3	144.7	183.9
Income (loss) from discontinued operations, net of tax	0.3	(0.9)	(1.6)	2.8
Net income attributable to HealthSouth common shareholders	$ 53.1	$ 52.4	$ 143.1	$ 186.7
Denominator
Diluted weighted average common shares outstanding	101.5	100.5	101.4	100.7
Diluted earnings per share attributable to HealthSouth common shareholders:
Continuing operations	$ 0.52	$ 0.53	$ 1.43	$ 1.82
Discontinued operations	0	(0.01)	(0.02)	0.03
Net Income	$ 0.52	$ 0.52	$ 1.41	$ 1.85

Earnings per Common Share - T69

Earnings per Common Share - Table 2 (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share [Abstract]
Basic weighted average common shares outstanding	90.6	86.5	89.1	86.8
Convertible perpetual preferred stock	0	3.2	1.3	3.2
Convertible senior subordinated notes	8.4	8.2	8.3	8.1
Restricted stock awards, dilutive stock options, restricted stock units, and common stock warrants	2.5	2.6	2.7	2.6
Diluted weighted average common shares outstanding	101.5	100.5	101.4	100.7

Earnings per Common Share - Tex

Earnings per Common Share - Textual (Details) - USD ($) $ / shares in Units, $ in Millions

Oct. 23, 2015

Jul. 16, 2015

Oct. 31, 2015

Jul. 31, 2015

May. 31, 2015

Apr. 30, 2015

Feb. 28, 2015

Jan. 31, 2015

Oct. 31, 2014

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Oct. 01, 2015

Apr. 23, 2015

Apr. 22, 2015

Dec. 31, 2014

Earnings per Common Share (Textual) [Abstract]

Cash dividends per common share, Declared

$ 0.23

$ 0.21

$ 0.65

$ 0.57

Common Stock

Earnings per Common Share (Textual) [Abstract]

Cash dividends per common share, Declared

$ 0.23

$ 0.21

$ 0.21

$ 0.21

Cash dividends per common share, Paid

$ 0.21

$ 0.21

$ 0.21

Dividends Payable, Current

$ 21.7

$ 21.7

$ 18.6

Convertible Preferred Stock, Conversion Price

$ 33.9905

Common Stock, Par or Stated Value Per Share

$ 0.01

Convertible Preferred Stock, Shares Issued upon Conversion

3,271,415

Common Stock | Subsequent Event [Member]

Earnings per Common Share (Textual) [Abstract]

Cash dividends per common share, Declared

$ 0.23

Cash dividends per common share, Paid

$ 0.23

Convertible Preferred Stock [Member]

Earnings per Common Share (Textual) [Abstract]

Preferred Stock, Par or Stated Value Per Share

$ 0.10

Temporary Equity, Liquidation Preference Per Share

$ 1,000

Temporary Equity, Shares Outstanding

96,245

2.00% Convertible Senior Subordinated Notes due 2043 [Member]

Earnings per Common Share (Textual) [Abstract]

Debt Instrument, Convertible, Conversion Price

$ 39.65

$ 39.65

Debt Instrument, Convertible, Terms of Conversion Feature

25.2194 shares per $1,000 principal amount

2.00% Convertible Senior Subordinated Notes due 2043 [Member] | Subsequent Event [Member]

Earnings per Common Share (Textual) [Abstract]

Debt Instrument, Convertible, Conversion Price

$ 38.08

Debt Instrument, Convertible, Shares Issued Upon Conversion

26.2583